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ABSTRACT 
 
Studying protein-protein interactions has been vital for understanding how proteins 
function within the cell, how biological processes are strictly regulated by these 
interactions, and what molecular mechanisms underlie cellular functions and diseases. 
Recent biochemical and biophysical studies have provided evidence supporting that G 
protein-coupled receptors (GPCRs) can and do interact with one another to form dimers or 
larger oligomeric complexes, which may determine the structure and function of GPCRs, 
including receptor trafficking, scaffolding and signaling. This may help to understand the 
physiological roles of GPCRs and mechanisms underlying certain disease pathologies and 
to provide an alternative approach for drug intervention. 
Cannabinoid CB1 and dopamine D2 receptors are the most common GPCRs in the 
brain and exert a mutual regulation in brain functions involved in learning, memory and 
drug addiction. There is structural and functional evidence supporting the idea that CB1 
and D2 receptors physically interact with each other in hippocampal and striatal neurons to 
modulate their functions. Direct evidence supporting a physical interaction between the 
CB1 and D2 receptors was obtained from cultured HEK293 cells stably coexpressed with 
both receptors. 
This research project was designed to critically test the hypothesis that a specific 
protein sequence (i.e. motif) in the D2 receptor is responsible for in vitro protein-protein 
interactions between the CB1 and D2 receptors. To reach this goal, fusion proteins 
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containing various domains and motifs of the CB1 and D2 receptors were prepared and 
then used first to determine the domains of the CB1 and D2 receptors responsible for in 
vitro protein-protein interactions between CB1 and D2 receptors, and then to identify the 
specific motifs in the D2 receptor responsible for in vitro CB1 coupling with the D2 
receptors. The major method used in this study is in vitro pull-down assay, which uses a 
purified and tagged bait protein to generate a specific affinity support that is able to bind 
and purify a prey protein from a lysate sample. The present study provides the first 
evidence that CB1 intracellular C-terminal (CB1-CT) and D2 intracellular loop 3 (D2-IL3) 
can directly interact with each other, and that the specific motifs “D2-IL3(Ⅳ1)” and 
“D2-IL3(Ⅳ3)” in the D2 receptor are likely responsible for their in vitro coupling with the 
CB1 receptors.  
The results of the present study are invaluable for future research exploring in vivo 
protein-protein interaction between the CB1 and D2 receptors in the rat striatum by 
co-immunoprecipitation. Specifically, future studies will determine whether the identified 
specific motifs “D2-IL3(Ⅳ1)” and “D2-IL3(Ⅳ3)” in the D2 receptor are indeed critical for 
their in vivo coupling with the CB1 receptors. 
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1  INTRODUCTION 
 
1.1 Protein-Protein Interaction   
Protein-protein interactions, specific interactions between two or more proteins, play 
diverse central roles in numerous biological processes in cells. Studying protein-protein 
interactions has been vital for understanding how proteins function within the cell, how 
biological processes are strictly regulated by these interactions, and what molecular 
mechanisms underlie cellular functions and diseases. Protein-protein interaction is one of 
the main research fields in current functional proteomics. The availability of entire genome 
sequences of many organisms, proteomics-based protein profiling studies, and various 
high-throughput analysis techniques catalyze resurgence in protein-protein interaction 
exploration. 
     
1.1.1 Types of Protein-Protein Interactions 
    The structural and functional diversity of protein-protein interactions is primarily 
based on the composition, affinity, and whether the association is transient or stable. 
    Homo- and hetero-oligomeric interactions  Protein-protein interaction can occur 
between identical or different protein units (i.e. homo- or hetero-oligomers). Oligomers of 
identical or homologous protein units can be organized in an isologous or a heterologous 
way with structural symmetry (Goodsell and Olson, 2000). An isologous association 
involves the same surface on both monomers related by a 2-fold axes of symmetry and can 
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further oligomerize using a different interface (e.g. form a dimer of dimers with three 
2-fold axes of symmetry) (Nooren and Thornton, 2003b). In contrast to an isologous 
association, heterologous assemblies use different interfaces that, without a closed (cyclic) 
symmetry, can lead to infinite aggregation (Nooren and Thornton, 2003b). 
    Obligate and non-obligate interactions  Two different types of protein-protein 
interactions can be defined on the basis of whether the interaction is obligate or 
non-obligate. In an obligate protein-protein interaction, the involved protomers are often 
expressed simultaneously and co-localized upon synthesis, but they are not identified as 
stable structures on their own in vivo. It has been shown that such obligate complexes, 
which are generally also functionally obligate, are true for homo-oligomers but may occur 
in hetero-oligomeric interactions. Non-obligate interactions of protomers that exist 
independently are involved in many of the hetero-oligomeric complexes, such as 
intracellular signaling complexes and antibody-antigen, receptor-ligand and 
enzyme-inhibitor complexes, most of which perform a regulatory role as their biological 
function. However, some homo-oligomers can also assemble to form non-obligate 
interaction structures (Jones and Thornton, 1996; Nooren and Thornton, 2003b). 
    Transient and stable interactions  Protein-protein interactions can be characterized 
as transient or stable interaction based on the lifetime of the interaction complex. Stable 
interaction is usually a permanent interaction that exists as multi-subunit complexes, 
whereas transient interaction, as the name implies, is on/off or temporary in vivo and 
typically requires a set of conditions to trigger the interaction. For example, hemoglobin 
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and core RNA polymerase are two stable multi-subunit complex interactions, whereas the 
interaction between Gα and Gβγ subunits of G protein is transient. Both transient and 
stable interactions can be either weak or strong. Transient interactions are expected to be 
involved in the majority of cellular processes including protein modification, transport, 
folding, signaling, cell cycling, etc. Structurally or functionally obligate protein-protein 
interactions are generally stable, whereas non-obligate protein-protein interactions may be 
stable or transient (Nooren and Thornton, 2003a; 2003b). 
Many protein-protein interactions do not belong to distinct types. Rather, a continuum 
of protein-protein interaction can exist between obligate and non-obligate interactions. 
Furthermore, the stability of all the protein-protein interaction complexes extremely 
depends on the physiological environments, so that an interaction may be mainly transient 
in vivo but becomes stable under certain cellular conditions (Jones and Thornton, 1996; 
Nooren and Thornton, 2003b). 
 
1.1.2 Effects of Protein-Protein Interactions 
A single protein, which generally resides in a crowded environment with many 
potential binding partners, can interact with diverse partners under different cellular 
conditions to form dynamic interaction networks, resulting in different biological outcomes. 
The measurable effects of protein-protein interactions can be demonstrated in several 
different ways. 
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They serve a regulatory role  Either an upstream or a downstream action in 
intracellular signaling can be operated by protein-protein interactions (Nooren and 
Thornton, 2003a).  
They create new binding sites  Changing fragment organization related to the 
physiological domain swapping equilibrium or moving a substrate between or among 
subunits in protein-protein interactions may result ultimately in an intended end product to 
create some new binding sites for further interactions (Nooren and Thornton, 2003a; 
2003b). 
They alter kinetic properties of enzymes  This may be the consequence of subtle 
changes of protein-protein interactions at the level of an allosteric effect or substrate 
binding (Nooren and Thornton, 2003a). 
They activate or inactivate a protein  Interactions with different binding partners can 
lead to a change in affinity and specificity of a protein for its substrate, which may activate 
or inactivate a protein and even present a new function that neither protein can exhibit 
alone (Nooren and Thornton, 2003a). 
     
1.1.3 Control of Protein-Protein Interactions 
Interactions between proteins can be controlled by the protomer’s localization, altering 
local concentration and binding affinity, which may be determined by the expression, 
secretion, post-translational modification, translocation and stability of protein components, 
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ligands, and the physicochemical environment. The most important ways for the control of 
protein-protein interactions involve the following mechanisms. 
Encounter  An encounter of the interacting surfaces is necessary for the association 
of two or more proteins, which are required to be co-localized in time and space. Such 
encounters may occur between protein components, co-expressing or co-localizing within a 
compartment or residing in different compartments. Translocation by directed diffusion or 
transport is essential for the encounters of these proteins from different locations. 
Local concentration  Regulation mechanisms influencing the effective local 
concentration of proteins include gene-expression or secretion levels, temporary storage, 
protein degradation, diffusion or transport, and the local molecular environment. The local 
concentration can be increased through the localization by adjacent domains in 
multidomain proteins and the anchoring of proteins in a membrane (e.g. transmembrane 
protein oligomerization) or other structural complex (Nooren and Thornton, 2003b). 
Post-translational modifications  Post-translational modifications of proteins through 
enzymatic activity, such as phosphorylation, palmitoylation and glycosylation, can prevent 
or induce interactions with other proteins. For example, proteins containing the bromo 
domain can only bind with acetylated but not unmodified histones (Jones and Thornton, 
1996). 
Ligands  Protein-protein interactions can be regulated by small molecules or other 
proteins, which are required for interactions to occur or disrupt interactions. For example, 
GTP/GDP exchange controls the Gα-Gβγ subunit assembly of the hetero-trimeric G protein: 
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binding of GTP to G proteins motivates their subunits’ dissociation while binding of GDP 
promotes their subunits’ association. 
Local physicochemical environment  The mutual binding affinity of components of a 
protein-protein interaction complex can be affected by the alteration in physiological 
conditions, including the concentration of ions, chemicals or proteins, as well as the 
changes in PH and temperature. 
     
1.1.4 Techniques for Studying Protein-Protein Interactions 
    Discovery and verification of biologically relevant protein-protein interactions are the 
primary steps for understanding how, where and under what conditions the proteins can 
interact with each other in vivo and the functional implications of these interactions. To 
address the vast challenge of mapping protein-protein interactions, a variety of 
methodologies to expedite research in this area have recently been developed in the fields 
of molecular biology, biochemistry, proteomics and bioinformatics. 
 
1.1.4.1 Molecular Biology and Biochemistry Based Methods 
    Traditionally, protein-protein interactions have been studied by genetic, biophysical 
and biochemical techniques, such as yeast two-hybrid system, pull-down assay, 
co-immunoprecipitation (co-IP), cross-linking reagents, blot overlay or far western blot, 
fluorescence gel retardation assay (Park and Raines, 2004), gel-filtration chromatography 
(Wilton et al., 2004) and ubiquitin-based split-protein sensor (Droit et al., 2005). 
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Yeast two-hybrid system  This genetic method takes advantage of the eukaryotic 
transcription process to make predictions about protein-protein interactions. This method is 
based on the fact that an interacting protein pair will be able to bring together the DNA 
binding domain and activation domain of a transcription factor in vivo to create a functional 
activator of transcription. The interaction can be identified by the expression of linked 
reporter genes, which may be lacZ gene for color selection and auxotrophic LEU2, HIS3 
and ADE2 genes for growth selection (Cho et al., 2004). 
    Co-immunoprecipitation  This immunoprecipitation experiment is designed to purify 
a bait protein antigen together with its interacting partners employing a specific antibody 
against the bait protein (Bartlett et al., 2005; Liu et al., 2000). 
    Pull-down assay  This affinity chromatography method uses a purified and tagged or 
labeled bait protein to generate a specific affinity support, which will be able to bind and 
purify a prey protein from a lysate sample or other protein-containing mixtures (Lee et al., 
2002; Zou et al., 2005). 
    Blot overlay or far western blot  This technique includes fractionating proteins on 
SDS-PAGE, blotting proteins to PVDF or nitrocellulose membrane, and then detecting 
with a probe of interest, which is typically a bait protein properly labeled with radioisotope, 
biotin or chemiluminescence. When the detection is simply visualized with a specific 
antibody, this technique is often referred to as “Far Western blot” (Hall, 2004; Liu et al., 
2000). 
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    Cross-linking reagents  Nearest neighbors, who are suspected to interact with each 
other in vivo or in vitro, can be trapped in their complexes by chemical cross-linking 
reagents for further study (Grabarek and Gergely, 1990; Sinz, 2003).  
  
1.1.4.2 Mass Spectrometry (MS) Based Methods 
    This kind of technique is applied in concert with affinity-based methods, such as 
Co-IP and pull-down assays, to isolate interacting complexes and identify the component 
proteins employing standard mass spectral approaches. Briefly, MS-based methods 
generally involve the selective purification and enrichment of a bait protein and its binding 
partners from lysate samples, the digestion of isolated proteins into peptides using a 
protease such as trypsin, the analysis of peptide mixtures by mass spectrometry and the 
identification of interacting proteins by mass searching of bioinformatics databases (Figeys 
et al., 2001). 
 
1.1.4.3 Protein Microarrays 
    The production of functional protein microarrays promises an innovative assay 
platform for the screening and identification of specific protein-protein interactions from 
complex mixtures. Most of the current protein chips are carried out through the bait 
proteins immobilized on a surface to capture the target proteins in the sample solution. Due 
to their flexibility and multiplexing capacity, these highly parallel assays are not biased 
towards abundant proteins and the experimental conditions can be well controlled. For 
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example, the stringency of the binding activities can be adjusted by introducing different 
cofactors or inhibitors in the binding assays (Korf and Wiemann, 2005). 
 
1.1.4.4 Bioinformatics Methods 
    The development of experimental techniques for identifying protein–protein 
interactions has created the dilemma of how to effectively utilize the extensive amount of 
data gathered by these large-scale studies. Thus, as complementary ways for the high 
throughput experimental techniques, systematic bioinformatics methods have been 
developed for the study of protein-protein interactions, which include well known and 
novel approaches: data mining, annotation by sequence similarity, phylogenetic profiling, 
metabolic pathway mapping, gene neighbor and domain name fusion analyses (Droit et al., 
2005). These methods integrate the information from different approaches to build the 
protein-protein interaction network that can predict protein function and define how 
macromolecules interact within complex networks.     
In addition, a variety of cutting-edge technologies are utilized in the techniques 
described above for studying protein-protein interactions, which include nuclear magnetic 
resonance (NMR), fluorescence resonance energy transfer (FRET), surface plasmon 
resonance (SPR), circular dichroism (CD), isothermal titration calorimetry (ITC), 
fluorescence polarization (FP), protein fragment complementation assays (PCA), various 
two-hybrid systems and computational analysis (Greenfiled, 2004; Northup, 2004; 
Obenauer and Yaffe, 2004; Park and Raines, 2004; Velazquez-Campoy et al., 2004). All the 
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readily reproducible methods demonstrate how to explore protein interaction partners, 
monitor protein-protein interactions as they occur in living cells, identify interaction 
interfaces, and qualitatively or quantitatively measure protein-protein interactions in vivo or 
in vitro. 
 
1.1.5 Protein-Protein Interactions of GPCRs 
    All G protein-coupled receptors (GPCRs) share a common general structure 
constituted by seven transmembrane (TM) helices linked by three extracellular and three 
intracellular loops, an extracellular amino terminal, and an intracellular carboxyl tail (Ji et 
al., 1998). This topology of GPCRs allows several potential faces for their protein-protein 
interactions. Because the extracellular loops are short, the N-terminal, which can be very 
extensive, is likely to dominate the extracellular interactions of GPCRs. With respect to the 
intracellular regions, both the C-terminal and third intracellular loop, which can be of 
considerable size, are the domains on which attention has been focused for the intracellular 
interactions of most GPCRs. Examples include the C-terminal and third intracellular loop 
of ß-adrenoceptors, the C-terminal of 5-HT2 receptors and the third intracellular loop of the 
dopamine D2 receptor (Milligan and White, 2001). 
    Most GPCRs contain sequence motifs that are able to direct protein-protein 
interactions and, thus, have the theoretical capacity to selectively interact with a host of 
other proteins. In fact, recent studies have identified several interaction domains on both 
extracellular and intracellular faces of GPCRs, which are responsible for the 
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protein-protein interactions of GPCRs, and undoubtedly, more domains wait to be defined 
(Lee et al., 2002; Liu et al., 2000; Scarselli et al., 2001; Zou et al., 2005). GPCR-protein 
assemblies, including interactions between receptor and receptor, receptor and 
receptor-interacting proteins, or receptor and G-protein, should be viewed as dynamic 
complexes ranging from transient interactions to more stable interactions, all of which vary 
with cell background and contribute to the finely tuned processes of downstream cell 
signaling (Milligan and White, 2001). Recently, there has been great interest in 
protein-protein interactions between individual GPCRs that induce the formation of homo- 
or hetero-dimer/oligomers.  
More recent biochemical and biophysical studies have provided several lines of 
evidence that GPCRs can and do interact with one another to form dimers or larger 
oligomeric complexes, which involve both homo-dimer/oligomers containing two or 
multiple copies of the same gene product and hetero-dimer/oligomers comprising more 
than one receptor. It is now widely accepted that GPCRs homo-dimerize/oligomerize for 
ligand binding and signal transduction to exert their functions. Data support that most 
members of the GPCR superfamily exist or can exist as homo-dimers/oligomers, which are 
revealed in dopamine, opioid, somatostatin and thyrotropin-releasing hormone receptors, 
β2-adrenergic receptor, muscarinic m3 acetylcholine receptor, CB1 cannabinoid receptor, 
etc (Lee et al., 2003; Milligan, 2001; Wager-Miller et al., 2002). In addition, a range of 
hetero-dimer/oligomeric interactions have been detected, which include not only those 
occurring between closely related GPCR subtypes, such as γ-aminobutyric acid 
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(GABA)BR1 and GABABR2 receptors, serotonin 5-HT1D and 5-HT1B receptors, 
somatostatin SSTR1 and SSTR5 receptors, dopamine D2 and D3 receptors, κ and δ opioid 
receptors, as well as μ and δ opioid receptors, but also more distantly related GPCRs, such 
as somatostatin SSTR5 and dopamine D2 receptors, dopamine D1 and adenosine A1 
receptors, α2 adrenergic and M3 muscarinic receptors, as well as angiotensin AT1 and 
bradykinin B2 receptors (Jordan and Devi, 1999; Lee et al., 2003; Marshall, 2001; Milligan, 
2001; Park et al., 2004; Scarselli et al., 2001; Vazquez-Prado et al., 2002). Two models to 
describe the dimerization of GPCRs have been proposed: the domain-swapped dimer 
model whereby transmembrane domains 1-5 of one protein couple with transmembrane 
domains 6 and 7 from the other protein to form the binding sites in the dimer, and the 
contact dimer model, which is formed by lateral packing of the individual polypeptides and 
may be the most likely structure for heterodimer formation (Marshall, 2001; Milligan, 
2001). 
Although the full functional and physiological significance of many interactions 
between GPCRs is not completely understood, current information indicates that these 
interactions might determine the structure and function of GPCRs, which have implications 
for receptor trafficking, scaffolding and signaling. This may help to understand the 
physiological roles of these receptors, and may underlie certain disease pathologies and 
provide an alternative approach for drug intervention. 
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1.2 Cannabinoid CB1 Receptor 
Cannabinoids (marijuana, cannabis) have a long history of consumption for 
recreational and medical reasons. The effects of cannabinoids are mediated by two 
subtypes of G protein-coupled cannabinoid receptors: CB1 and CB2 receptors. The present 
study focuses on CB1 receptors, which are found primarily in the CNS, with the highest 
density in the hippocampus, cerebellum and basal ganglia. This distribution pattern 
correlates well with the effects of cannabinoids on memory, perception and the control of 
movement (Ameri, 1999). CB1 receptors bound by cannabinoids can modulate inhibition 
of adenylate cyclase activity, stimulation of inwardly rectifying potassium channels, 
inhibition of N- and P/Q-type voltage-dependent calcium channels, and activation of 
mitogen-activated protein (MAP) kinase pathway (Howlett, 1998). 
  
1.2.1 Structure and Property of CB1 Receptor 
    The cDNA sequence encoding the 473-amino-acid protein product of the CB1 
receptor was isolated from a rat cerebral cortex cDNA library (Matsuda et al., 1990) and a 
human brain stem cDNA library (Gerard et al., 1991). The gene locus for the human CB1 
receptor has been genetically mapped to chromosome 6q14-q15 (Hoehe et al., 1991).  
    The CB1 receptor exhibits the basic structural features predicted for a GPCR (Figure 
1.1) (Bramblett et al., 1995). The apparent molecular weight of the CB1 receptor is 64 kDa 
when detected with an antipeptide antibody in immuno-blots. Reducing the apparent 
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weight of this receptor to 59 and 53 kDa by the treatment with endoglycosidases F and/or 
H indicates that it is glycosylated (Song and Howlett, 1995). 
 
 
 
 
 
 
 Figure 1.1: The cannabinoid CB1 receptor model of Reggio comprising seven   
hydrophobic transmembrane domain regions that extend through the plasma 
membrane, three extracellular loops (EL1/EL2/EL3), three intracellular loops 
(IL1/IL2/IL3), an extracellular N-terminal (NT) and an intracellular C-terminal (CT) 
[Modified from Howlett, 1998]. 
 
 
 
 14
1.2.2 Signal Transduction Mediated by CB1 Receptor 
Cannabinoid CB1 receptors couple to multiple signal transduction pathways that 
inhibit adenylate cyclase activity, modulate ion channels, and activate MAP kinase 
pathway (Figure 1.2). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Signal transduction mechanisms stimulated by the CB1 receptor in a 
presynaptic nerve terminal. Activation of the CB1 receptor stimulates its coupling 
to G protein, which transduces the stimulation of MAP kinase, and the inhibition of 
adenylate cyclase, thereby attenuating the production of cAMP. Moreover, the G 
protein directly couples CB1 receptors to N- and Q/P-type voltage-dependent 
calcium channels for inhibition, and to inwardly rectifying potassium channels (K+ir) 
for stimulation. The G protein-dependent activation of the A-type potassium current 
(K+A) is modulated via the inhibition of adenylate cyclase [Taken from Ameri, 
1999]. 
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1.2.2.1 Inhibition of Adenylate Cyclase 
Three lines of evidence suggest that cannabinoids act on the CB1 receptors to inhibit 
adenylate cyclase in a reversible, dose-dependent, and stereoselective manner, resulting in 
the attenuation of cAMP production (Bidaut-Russell et al., 1990; Howlett et al., 1986). 
Firstly, cellular selectivity of an inhibition of adenylate cyclase, which is not observed in 
either the soluble adenylate cyclase from rat sperm or in non-membrane-bound adenylate 
cyclase preparations from different cell lines, provides evidence for the existence of 
specific receptors for cannabimimetic compounds (Ameri, 1999). Secondly, brain regions 
in which cannabinoids are most effective inhibitors of adenylate cyclase are hippocampus, 
basal ganglia and cerebellum displaying the highest density of CB1 receptors 
(Bidaut-Russell et al., 1990). Finally, it has been shown that the selective CB1 receptor 
antagonist SR141716A can antagonize the inhibition of cAMP production induced by 
cannabinoids (Rinaldi-Carmona et al., 1994).  
The involvement of an inhibitory G protein (Gαi/o) through which CB1 receptors are 
negatively coupled to adenylate cyclase has been clearly demonstrated, because 
cannabinoid-induced inhibition of adenylate cyclase can be blocked by pertussis toxin in 
mammalian brain and in cultured neuronal cells (Bidaut-Russell et al., 1990; Howlett et al., 
1986; Pacheco et al., 1993). Moreover, cannabinoid regulation of adenylate cyclase is 
sensitive to divalent cations, such as Mg2+ or Mn2+, and guanine nucleotides in a manner 
characteristic for other Gαi/o protein-coupled receptors (Ameri, 1999).  
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The CB1 receptor is also known to share G proteins with other GPCRs, such as opioid 
receptor, dopamine D2 receptor and GABAB receptor, as demonstrated by additivity 
experiments in cultured cerebellar granule cells (Childers et al., 1992; Pacheco et al., 1993) 
and striatal slices (Bidaut-Russell and Howlett, 1991) (Figure 1.3). 
 
 
 
       
 
 
 
 
 
 
 
 
 
Figure 1.3: Schematic diagram illustrating the possible interaction of the cannabinoid CB1 
receptor with other Gαi/o-coupled receptors, such as opioid receptor, dopamine D2 
receptor and GABAB receptor [Taken from Ameri, 1999]. 
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1.2.2.2 Modulation of Ion Channels 
    Gαi/o proteins not only mediate an attenuation of cAMP production by coupling 
various receptors to adenylate cyclase, but also modulate receptor activity by coupling to 
ion channels. The CB1 receptor has been reported to modulate the activity of N- and 
P/Q-type voltage-dependent calcium channels and to enhance the activation of the 
voltage-dependent A-type potassium channel and inwardly rectifying potassium channel 
(Ameri, 1999) (Figure 1.2). 
It has been reported that cannabinoids exert an inhibitory effect on voltage-activated 
inward calcium currents executed by the N-type and P/Q-type calcium channels in primary 
neurons (Pan et al., 1996) and diverse neuroblastoma cell lines expressing CB1 receptors 
(Caulfield and Brown, 1992; Mackie and Hille, 1992). The inhibition of calcium currents 
by cannabinoids could be attenuated by the selective N-type calcium channel blocker 
ω-conotoxin GVIA and by the selective P/Q-type blocker ω-agatoxin (Caulfield and 
Brown, 1992; Mackie and Hille, 1992). Furthermore, electrophysiological studies have 
shown that inhibition of the N-type calcium current by cannabinoids is stereospecific, 
pertussis toxin-sensitive, and can be inhibited by the selective CB1 receptor antagonist 
SR141716A, indicating a CB1 receptor-mediated process (Twitchell et al., 1997). Taken 
together, these results demonstrate the inhibition of N- and P/Q-type voltage-dependent 
calcium channels mediated by CB1 receptors in neurons.  
Cannabinoids have been shown to enhance the inwardly rectifying potassium current 
in murine tumor cells and in Xenopus oocytes expressing CB1 receptors (Henry and 
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Chavkin, 1995; Mackie et al., 1995). It has been reported that the CB1 receptor can be 
phosphorylated by protein kinase C, leading to a reduced ability of cannabinoids to activate 
inwardly rectifying potassium currents and to attenuate P/Q-type calcium currents in a cell 
line transfected with rat CB1 receptors (Garcia et al., 1998). Moreover, Deadwyler et al. 
(1993) showed that the voltage dependence of the rapidly inactivating potassium A current 
was significantly altered in a concentration-dependent manner by cannabinoid analogs. 
Recent evidence indicates that cannabinoid-induced stimulation of this potassium current is 
cAMP-dependent and results from CB1 receptor-mediated inhibition of adenylate cyclase 
and subsequent inhibition of protein phosphorylation of the A-type potassium channel 
protein (Figure 1.2), but not through a direct coupling of Gαi proteins to the A-type 
potassium channel (Hampson et al., 1995). 
 
1.2.2.3 Activation of MAP Kinase 
Stimulation of MAP kinase is the third well-characterized messenger system mediated 
by the CB1 receptor. Thus far, activation of the MAP kinase pathway induced by the CB1 
receptor has only been identified in cell lines, so that it is still uncertain if this plays a 
significant physiological role in the CNS. It has been demonstrated that cannabinoids are 
highly potent activators of MAP kinase phosphorylation in stably transfected Chinese 
hamster ovary cells expressing human CB1 receptors. This effect can be inhibited by the 
selective antagonist SR141716A, implying an involvement of the CB1 receptor. 
Furthermore, it has been shown that the signal transduction pathway between CB1 receptor 
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and MAP kinase involves a pertussis toxin-sensitive G protein (Gβγ subunits), and is 
independent of the cannabinoid-induced inhibition of cAMP production (Bouaboula et al., 
1995b) 
. 
1.2.3 Distribution and Function of CB1 Receptor in the CNS 
    The CB1 receptor is one of the most abundantly expressed neuronal receptors in the 
CNS and its distribution has been well characterized in rat and human brains using various 
techniques: receptor binding and autoradiography, reverse-transcription polymerase chain 
reaction (RT-PCR), northern blot, in situ hybridization, and immunohistochemistry (Ameri, 
1999; Glass et al., 1997; Herkenham et al., 1991b; Tsou et al., 1998). These studies exhibit 
a widespread distribution of the CB1 receptor in those brain regions known to be tightly 
involved in learning and memory, brain reward, antinociception, anticonvulsion, and 
movement control. 
    Autoradiographic studies employing a radioactive cannabinoid have shown that the 
specific, saturable, high affinity CB1 binding sites are not distributed homogeneously in 
the brain. The highest density has been detected in the basal ganglia (globus pallidus, 
enteropeduncular nucleus, substantia nigra and lateral caudate putamen) and the molecular 
layer of the cerebellum, which is consistent with the notable effects of cannabinoids on a 
decrease in spontaneous locomotor activity in rodents. High binding densities have been 
also demonstrated in the dentate gyrus, pyramidal cell layers of the hippocampus, and the 
cortex, which may provide a basis to explain an involvement of cannabinoids in the 
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impairment of cognition and memory, and also the anticonvulsive effects of these 
compounds. The intermediate levels of binding sites have been found in the nucleus 
accumbens, which is correlated with modulating brain reward. Small nuclei with high 
density of binding are also found in other areas of hypothalamus, brain stem and pituitary 
gland for controlling body temperature, pain and hormone function (Ameri, 1999; 
Herkenham et al., 1991b). 
    Immunohistochemical studies on distribution of the CB1 receptor in the adult rat brain 
have not only shown results consistent with findings of the autoradiographic studies, but 
also presented intriguing new data about the identification of particular neuronal cell fibers 
that possess CB1 receptors. Thus, CB1 receptor-like immunoreactive axons, cell bodies 
and dendrites have been found to be widely distributed in the forebrain and sparsely in the 
hindbrain and the spinal cord. The intensely stained neurons were dispersed in cortical 
structures including the olfactory bulb and hippocampal formation, while moderately or 
lightly stained neurons were detected in the amygdala and caudate-putamen. Beaded 
immunoreactive fibers were also found in the periaqueductal gray and dorsal horn and 
lamina X of the spinal cord, which are important regions in ascending pain transmission, in 
which the CB1 receptor is expected to be involved in the antinociception induced by 
cannabinoids (Ameri, 1999; Tsou et al., 1998). 
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1.3 Dopamine D2 Receptor 
Dopamine (DA) is the most important catecholamine neurotransmitter in the 
mammalian brain where it is involved in a variety of functions including locomotor activity, 
learning and memory, emotion, reward, food intake, and endocrine regulation (Missale et 
al., 1998). The actions of DA are mediated via GPCRs and the cDNA sequences of five 
distinct G protein-coupled DA receptor subtypes (D1-D5) have been isolated and 
characterized. These receptors have been categorized into two groups based on sequence 
similarity, functional characteristics and pharmacological profiles: D1-like (D1, D5) 
receptors that activate adenylyl cyclase, leading to an increase in intracellular cAMP levels, 
and D2-like (D2, D3, D4) receptors that inhibit adenylyl cyclase and modulate calcium and 
potassium ion channels (Mustard et al., 2005). The D2 receptor has been found mainly in 
the substantia nigra pars compacta, ventral tegmental area, striatum (which includes the 
shell and core of the nucleus accumbens and dorsal striatum), olfactory tubercule, and 
pituitary gland (Bonic and Hopf, 2005; Jackson and Westlind-Danielsson, 1994).  
 
1.3.1 Structure and Variants of dopamine D2 Receptor 
The cDNA sequence encoding the D2 receptor was first isolated in 1988 (Bunzow et al., 
1988) and subsequently, the existence of splice variants of this receptor was revealed in 
1989 (Giros et al., 1989). It seems likely that many of the genes in the GPCR family have 
arisen from a single primordial gene that lost its intron by a gene-processing event (Missale 
et al., 1998). The gene encoding the D2 receptor is interrupted by intron, which allows the 
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generation of receptor variants. Indeed, the D2 receptor has two main variants, named D2(S) 
(415aa) and D2(L) (444aa), which are generated by alternative splicing of a 87-bp exon 
between introns 4 and 5 (Giros et al., 1989). 
As a member of the GPCR family, the D2 receptor has seven transmembrane domains, 
three intra- and three extra-cellular loops, an intracellular C-terminal, and an extracellular 
N-terminal (O'Dowd, 1993; Missale et al., 1998). The D2 receptor has a long intracellular 
loop 3 (Figure 1.4) that seems to play a central role in receptor coupling (O'Dowd, 1993).  
Although D2(L) differs from D2(S) by the insertion of a stretch of 29 amino acids in 
the intracellular loop 3, thus far very few differences have emerged between these two D2 
receptor variants in terms of their distribution and function. Both of them display the same 
distribution pattern with the shorter form less abundantly transcribed, and reveal the same 
pharmacological profile, even if a marginal difference in affinities of sulpiride and 
raclopride for these two isoforms has been reported (Giros et al., 1989). When expressed in 
host cell lines, both variants inhibited adenylate cyclase but the D2(S) receptor displayed 
higher affinity in this effect (Missale et al., 1998). I chose to focus on the D2(L) receptor 
for this research project as its expression is the most abundant in the brain (Martres et al., 
1992; Neve et al., 1991). 
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Figure 1.4: The dopamine D2 receptor model comprising seven hydrophobic 
transmembrane domain regions that extend through the plasma membrane, three 
extracellular loops, three intracellular loops (including the longest domain: 
intracellular loop 3, which was divided into five sections in the present study), an 
extracellular N-terminal and an intracellular C-terminal (Modified from 
http://www.gpcr.org). 
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1.3.2 Signal Transduction Mediated by D2 Receptor 
    Signal transduction of the D2 receptor is mediated by the heterotrimeric G proteins of 
Gαi/o. These pertussis toxin-sensitive G proteins regulate not only adenylate cyclase via 
their Gα subunits, but also ion channels, phospholipases, protein kinases, and MAP kinases, 
as a result of the receptor-induced liberation of Gβγ subunits (Bonic and Hopf, 2005). In 
addition to the interactions between the D2 receptor and G proteins, other protein-protein 
interactions (i.e. receptor oligomerization, receptor interactions with scaffolding and 
signal-switching proteins or other receptors) are also critical for regulation of D2 receptor 
signaling. 
    The D2 receptor inhibiting adenylate cyclase was initially shown in early 1980s in the 
CNS (Missale et al., 1998). Recently, several lines of evidence further confirmed that D2 
receptors are Gαi/o protein linked, which can release Gα and Gβγ subunits (Bonic and Hopf, 
2005; Neve et al., 2004). Classically, the function of the D2 receptor has been thought to 
antagonize cAMP-dependent signaling, where Gαi subunits bind to and inhibit adenylyl 
cyclases, accordingly preventing production of cAMP and activation of protein kinase A 
(Figure 1.5 A). 
D2 receptors also modulate intracellular signaling through Gβγ subunits, which can 
act on a number of intracellular targets: ion channels, phospholipases, protein kinases, and 
MAP kinase (Neve et al., 2004). It has been shown that direct interaction of Gβγ with 
several types of ion channels can influence the stimulation of potassium currents and 
inhibition of some calcium channels. Gβγ subunits have also been revealed to facilitate 
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calcium release from intracellular calcium stores (Missale et al., 1998). Moreover, Gβγ 
subunits can activate MAP kinase system through several different pathways, which may 
involve phosphinositide 3-kinase, Ras, and transactivation of a growth factor receptor 
(Bonic and Hopf, 2005) (Figure 1.5 A). 
    It has recently been shown that β-arrestin 2 can facilitate D2 receptor signaling in 
addition to its canonical role in receptor internalization. The D2 receptor may inhibit 
activity of the serine/threonine protein kinase (Akt) by a β-arrestin 2-dependent mechanism. 
This effect occurs through a newly discovered β-arrestin/ kinase/phosphatase signaling 
complex that is independent from the traditional cAMP-dependent pathway (Figure 1.5B). 
These results indicate that β-arrestin appears to be critical in signal transduction of the D2 
receptor to regulate dopamine-dependent dephosphorylation of Akt and its downstream 
target glycogen synthase kinase (GSK) by allowing a specific association between Akt and 
the phosphatase PP2A (Bonic and Hopf, 2005).  
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Figure 1.5: The dopamine D2 receptor intracellular signaling pathways: the inhibition of 
cAMP signaling through Gαi and multiple Gβγ-dependent signaling pathways (A), 
as well as the inhibition of Akt signaling through the signaling complex β-arrestin 
2/kinase(Akt)/phosphatase(PP2A) (B) [Taken from Bonic and Hopf, 2005]. 
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1.3.3 Distribution and Function of D2 Receptor in the Brain 
Application of in situ hybridization with cloned D2 receptor probes and 
immunohistochemical analysis with specific anti-D2 antibodies has made it possible to 
define the cellular and subcellular localization of D2 receptors in specific brain regions. 
The D2 receptor has been preferentially located in the striatum (including the dorsal 
striatum and the shell and core of the nucleus accumbens) where stimulation of D2 
receptors is essential for the enabling role of striatal dopamine on various behavior. The D2 
receptor has also been identified in the substantia nigra pars compacta, the ventral 
tegmental area and the hypothalamus where dopaminergic neurons are expressed to give 
origins to three main pathways in the brain, i.e. nigrostriatal, mesolimbocortical and 
tuberoinfundibular pathways. In addition, the D2 receptor mRNAs have been found in the 
prefrontal, cingulate, temporal, and enthorinal cortices, septal region, amygdala, olfactory 
tubercule, pituitary gland, and granule cells of the hippocampus (Jackson and 
Westlind-Danielsson, 1994; Missale et al., 1998). 
Immunohistochemical analysis has demonstrated that D2 receptors are located in 
medium spiny neurons of the striatum where they are more concentrated in spiny dendrites 
and spine heads than in the somata. D2 receptors are present in perikarya and dendrites 
within the substantia nigra pars compacta, and are much more concentrated in the external 
segment of the globus pallidus than in other striatal projections. D2 receptor 
immunoreactivity has also been detected in the glomerular and internal plexiform layers of 
the olfactory nerve, and central nucleus of the amygdala (Levey et al., 1993). 
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The location of D2 receptors in the above brain regions suggests their important 
involvement in locomotor activity, learning and memory and drug addiction. This idea is 
supported by recent pharmacological and behavioral studies on the relation of D2 receptors 
with locomotor activity (Berke and Hyman, 2000; Jackson and Westlind-Danielsson, 1994; 
Missale et al., 1998), learning and memory (Arnsten et al., 1995; Berke and Hyman, 2000; 
Missale et al., 1998; Schultz et al., 1993) and drug addiction (Missale et al., 1998; Self et 
al., 1996). 
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1.4 CB1 and D2 Receptors Are Involved in Learning and Memory 
 
1.4.1 Cannabinoids Impair Learning and Memory via Hippocampal CB1 Receptors 
    The naturally occurring cannabinoids (such as Δ9-THC) and synthetic compounds 
(such as HU210) are known to produce acute impairing effects on learning and memory in 
animals (Carlini et al., 1970; Winnicka et al., 2003) and humans (Abel, 1971). Prevention 
of Δ9-THC-induced deficits in radial-maze choice accuracy and in delayed 
non-match-to-position tasks by SR141716A, a specific CB1 receptor antagonist, provides 
strong evidence that Δ9-THC impairs working memory processes through a direct action 
on CB1 receptors (Beninger and Mallet, 1998; Martin and Lichtman, 1996). The important 
role of CB1 receptors in memory is further supported by the findings that blockade of CB1 
receptors improves cognitive progresses observed in the social recognition task in rats 
(Terranova et al., 1996), and that recognition memory is enhanced in CB1 receptor 
knock-out mice (Imperato et al., 1999). 
The hippocampus and its related structures appear to be pivotal for memory as its 
damage by surgical or chemical methods severely impairs performance in a variety of 
memory tasks (McLamb et al., 1988; Olton and Werz 1978). Several observations are 
consistent with the notion that the hippocampus regulates the disruptive effects of 
cannabinoids on memory (Hill et al., 2004; Martin et al., 1995). This notion is also 
supported by the fact that hippocampus displays a high density of CB1 receptors (Tsou et 
al., 1998) and high endocannabinoid levels (Di Marzo et al., 2000). 
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Cannabinoids have been shown to modulate hippocampal cholinergic 
neurotransmission, which has been suggested by ample evidence to play an important role 
in learning and memory: increased acetylcholine output in the hippocampus positively 
correlates with learning and memory (Fadda et al., 1999; Kim and Levin, 1996; Morley et 
al., 2000). Studies suggest that cannabinoids inhibit long-term potentiation and reduce 
hippocampal neurotransmitter release, in particular acetylcholine (Davies et al., 2002; 
Schlicker and Kathmann, 2001). Δ9-THC and synthetic cannabinoid CB1 receptor agonists 
have been reported to reduce acetylcholine release in vivo from the rat hippocampus (Carta 
et al., 1998; Gessa et al., 1998, 2000) and to inhibit electrically evoked acetylcholine 
release in vitro from hippocampal slices (Gifford and Ashby, 1996). These findings 
suggest that cannabinoid-induced impairment of learning and memory may be related to a 
reduction in acetylcholine neurotransmission in the hippocampus. 
   
1.4.2 Hippocampal D2 Receptor System Modulates Cannabinoid-induced Learning 
and Memory Impairment 
    Memory function appears to be affected by manipulations of hippocampal dopamine 
D2 receptor system. Dopamine innervation of the hippocampus plays a significant role in 
spatial working memory and specifically, D2 receptors in the ventral hippocampus were 
clearly related to choice accuracy performance in the radial-arm maze (Levin and 
Wilkerson, 1999). Hippocampal dopamine systems may influence learning and memory 
function via interactions with the well-documented hippocampal acetylcholine systems. 
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Ingram et al. (2001) confirmed the important role of ventral hippocampal D2 receptors in 
complex learning, which is likely mediated by D2 receptor-induced acetylcholine release 
in this brain region. According to these data, it is suggestive that hippocampal D2 receptor 
system modulates learning and memory by regulating acetylcholine release. 
Several lines of evidence suggest that hippocampal dopamine D2 receptor system is 
involved in the modulation of cannabinoid-induced learning and memory impairment and 
decreased acetylcholine release. Nomikos et al. (2003) showed that D2 receptor activation 
mediates high-dose cannabinoid-induced inhibitory effects on acetylcholine release. 
Moreover, it has been observed that cannabinoids-induced memory impairment and 
reduction of acetylcholine release in the hippocampus could be antagonized by the D2 
dopamine receptor antagonist S(–)-sulpiride and be potentiated by the D2 dopamine 
receptor agonist (–)-quinpirole, indicating that hippocampal dopamine D2 receptor is 
critically involved in the process of cannabinoid-induced memory impairment (Gessa et al., 
2000). These results imply that CB1 and D2 receptors may work together in order to 
regulate learning and memory, thus providing the functional evidence supporting the 
existence of CB1 receptors coupling with D2 receptors. 
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1.5 CB1 and D2 Receptors Are Involved in Drug Addiction 
 
1.5.1 Mesolimibic Dopaminergic System in Drug Addiction 
    Drug addiction is a psychiatric disorder in which neuronal mechanisms underlying 
learning and memory are malfunctioning (Berke and Hyman, 2000; Stelt and Di Marzo, 
2003). A common feature for the major drugs of abuse, such as amphetamine, cocaine and 
opioids including morphine and heroin, is their stimulation of the mesolimbic 
dopaminergic system, which has an essential role in the acquisition of natural reward and 
drug-seeking behavior (Spanagel and Weiss, 1999). This neurotransmitter system includes 
the midbrain dopaminergic projection from the ventral tegmental area (VTA) to structures 
closely associated with the limbic system, most prominently the nucleus accumbens shell 
region and the prefrontal cortex. Because of its ubiquitous involvement in the regulation of 
reward-related behavior, this system has been characterized as a neurochemical substrate of 
brain reward (Missale et al., 1998). 
Pharmacological studies have shown that D2 receptors are involved in the mesolimbic 
dopaminergic system regulating the reward-related behavior, with its agonists or 
antagonists respectively stimulating or inhibiting this behavior. It has been reported that 
suppression of morphine-induced place preference was observed in mice that lack D2 
receptors (Maldonado et al., 1997). Another study has showed that D2 receptor agonists 
enhanced reinstatement of cocaine-seeking behavior (Self et al., 1996). In the case of 
alcohol drinking, D2 receptor antagonists administered either systemically or locally into 
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the nucleus accumbens decrease home-cage drinking and operant responses to alcohol 
(Spanagel and Weiss, 1999).  
 
1.5.2 Endocannabinoid System Modulates Mesolimibic Dopaminergic Pathway 
    Endocannabinoid system constituted with the cannabinoid receptors, 
endocannabinoids and proteins for their biosynthesis and degradation is implicated in the 
regulation of brain reward (Ameri, 1999). The fact that CB1 receptor is the target of 
cannabinoids, the psychoactive compounds of marijuana, provides support for the role of 
these receptors in reward related processes. Activation of mesolimbic dopamine neurons in 
the VTA and subsequent increased release of DA in the nucleus accumbens have been 
identified after systemic administration of CB1 receptor agonists, which could be blocked 
by selective CB1 receptor antagonists (French, 1997; Gessa et al., 1998; Wu and French, 
2000). These findings suggest that endocannabinoids activating presynaptic CB1 receptors 
may modify dopaminergic transmission in the mesolimbic reward pathway through 
protein-protein interactions between cannabinoid and dopamine receptors. This working 
hypothesis is further supported by the findings that dopamine and endocannabinoid systems 
exert a mutual control on each other, by which dopaminergic D2-like receptors may 
regulate cannabinergic CB1 receptors in the striatum (Giuffrida et al., 1999; Stelt and Di 
Marzo, 2003).  
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1.6 Research Project 
 
1.6.1 Background 
Both CB1 and D2 receptors are highly expressed in the basal ganglia and 
hippocampus (Glass et al., 1997; Herkenham et al., 1991b; Tsou et al., 1998), suggesting 
that both receptors may interact with one another. Recent evidence further showed that 
CB1 and D2 receptors are co-expressed in the same neurons. In the hippocampus, 
coexpression of CB1 and D2 receptors was detected in the dentate gyrus, where D2 
hybridization signals were detected in 88% of the low-CB1-expressing cells, and 48% of 
all D2-positive cells coexpress CB1 receptors (Hermann et al., 2002). In contrast, CB1 and 
D2 receptor mRNAs are extensively co-localized in the striatum: 73% D2-positive cells 
contain CB1 receptor hybridization signals (Hermann et al., 2002). These findings provide 
structural evidence supporting the possibility that CB1 and D2 receptors may physically 
interact to each other in hippocampal and striatal neurons. 
    This idea is further supported by various lines of evidence suggesting functional links 
between CB1 and D2 receptors. While stimulation of either CB1 receptors or D2 receptors 
leads to a decrease in cAMP accumulation, an increase in cAMP levels is promoted by 
switching the coupling of the CB1 receptor from Gαi/o to Gαs when both CB1 and D2 
receptors are stimulated together (Glass and Felder, 1997; Jarrahian et al., 2004). Acute 
learning and memory impairment induced by cannabinoids through CB1 receptors in the 
hippocampus can be antagonized by the D2 receptor antagonist S(–)-sulpiride and 
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potentiated by the D2 receptor agonist (–)-quinpirole, suggesting that D2 receptors are 
involved in the modulation of cannabinoid-induced learning and memory impairment by 
interacting with CB1 receptors (Gessa et al.，2000). It has been shown that dopamine and 
the endogenous cannabinoids display complex interactions in their control of basal ganglia 
circuitry and in the mesolimbic reward system (Giuffrida et al., 1999; Glass and Felder, 
1997; Jarrahian et al., 2004; Mailleux and Vanderhaeghen, 1993；Stelt and Di Marzo, 2003). 
Giuffrida et al. (1999) reported that chronic treatment with D2 receptor antagonists 
produced up-regulation of CB1 mRNA in the striatum. 
Direct evidence supporting the existence of CB1:D2 receptor complexes comes from 
the recent Co-IP experiment showing a physical interaction between cannabinoid CB1 and 
dopamine D2 receptors in HEK293 cells stably coexpressed both receptors (Kearn et al., 
2005). 
 
1.6.2 Hypothesis 
    In summary, all the available lines of evidence support the notion that the CB1 and D2 
receptors interact to each other both in vitro and in vivo. This research project will examine 
CB1 and D2 interaction in in vitro situation. Specifically, the central hypothesis of this 
project is that specific motifs in the D2 receptor are responsible for in vitro 
protein-protein interactions between cannabinoid CB1 and dopamine D2 receptors.  
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1.6.3 Objective 
    The purpose of this study is to identify the specific motifs in the D2 receptor that are 
responsible for in vitro coupling between CB1 and D2 receptors in HEK293 cells stably 
co-transfected with both receptors. Specifically, three objectives will be addressed in this 
project: 
1. To prepare over-expressed full length CB1 and D2 receptors and purified fusion 
proteins containing various domains and motifs of CB1 and D2 receptors;     
2. To determine the domains of the CB1 and D2 receptors responsible for in vitro 
protein-protein interactions between CB1 and D2 receptors; 
3. To identify the specific motifs in the D2 receptor responsible for in vitro 
protein-protein interactions between CB1 and D2 receptors. 
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2  MATERIALS AND METHODS 
 
2.1 Materials 
 
2.1.1 Vectors 
    In total, five original vectors were used for cloning and subcloning of the gene 
sequences of the CB1 and D2 receptors: two pGEX vectors (Amersham Biosciences, 
Piscataway, NJ) of “pGEX-2T” and “pGEX-6P-1”, “pET-28a(+)” (Novagen, Mississaga, 
ON), “pcDNA™3.1/myc-His(B)” (Invitrogen, Burlington, ON) and “pGEM-T Easy” 
(Promega, Madison, WI).  
The pGEX vectors (Figure 2.1) are responsible for the inducible, high-level 
intracellular expression of genes in E.coli cells as fusion proteins with GST. The 
pET-28a(+) vector (Figure 2.2) is designed for the over-expression of the 6His fusion 
proteins in E.coli cells. The pGEM-T Easy vector (Figure 2.3) is applied to facilitate the 
PCR products for their subcloning. The pcDNA™3.1/myc-His(B) vector (Figure 2.4) is 
designed for the high-level expression and detection of tagged recombinant proteins in 
mammalian hosts.  
One more vector was reconstructed from the original “pcDNA™3.1/myc-His(B)” with 
the synthetic “FLAG epitope (DYKDDDDK)” (Invitrogen, Burlington, ON) incorporated 
by “SacII” (5´-CCGC↓GG-3´) & “SfuI” (5´-TT↓CGAA-3´) restriction sites, named as 
“pcDNA™3.1/FLAG(B)” (Figure 2.5), to express the FLAG tagged fusion proteins in 
mammalian cells.  
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Except for the pET-28a(+) vector with a kanamycin-resistant gene (kanr), all other 
vectors used here have an ampicillin-resistant gene (ampr) for selective amplification of 
recombinant plasmids. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Map of pGEX vectors, “pGEX-2T” and “pGEX-6P-1”, showing the reading 
frames and the multiple cloning sites. The underlined restriction sites were used in 
this study. (Modified from Amersham Biosciences) 
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Figure 2.2: Map of pET-28a(+) vector showing the reading frame as well as the cloning 
and expression region. The underlined restriction sites were used in the present 
study. (Modified from Novagen) 
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Figure 2.3: pGEM-T Easy Vector circle map illustrating the promoter and multiple cloning 
sequences. (Modified from Promega) 
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Figure 2.4: Map of pcDNA™3.1/myc-His(B) vector, illustrating the multiple cloning sites 
and expression regions. (Modified from Invitrogen) 
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Figure 2.5: Map of pcDNA™3.1/FLAG(B) vector, which was reconstructed from the 
original “pcDNA™3.1/myc-His(B)” with the synthetic “FLAG epitope 
(DYKDDDDK)” incorporated by “SacII” & “SfuI” restriction sites. (Modified from 
Invitrogen) 
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2.1.2 Competent E.coli Cells 
    Four strains of competent E.coli cells were used for the transformation of plasmids: 
DH5α, JM109, ER2925 and BL21. DH5α competent cells (aliquot 50 μl of cells for each 
transformation), which were directly used for transformation after purchased from 
Invitrogen (Burlington, ON) and had high transformation efficiency, were recommended 
for the transformation of routine subcloning into vectors to screen out the correct clones. 
The simple amplification of plasmids could be obtained from the transformation into 
JM109 cells (New England Biolabs, Ipswich, MA). ER2925 cells (New England Biolabs, 
Ipswich, MA) are useful for production of DNA to be cut with Dam, Dcm or CpG-sensitive 
restriction enzymes, such as “XhoI”, “SacII” and “SfuI”. BL21 and its lysogenized strain 
DE3 competent cells (New England Biolabs, Ipswich, MA) were respectively applied for 
inducing expression of GST or 6His fusion proteins after transformation. 
 
    Except for the DH5α competent cells, the other four strains of competent E.coli cells 
were prepared by the following procedures that were performed under sterile conditions.  
a. Pick a single clone from a freshly grown LB-agar plate (2% bacto-agar, Becton 
Dickinson, Sparks, MD, in LB media for autoclave, 10 ml for each 10 cm plate) of E. 
coli cells incubated at 37oC overnight and disperse it in 5 ml of LB media (1% 
bacto-tryptone, Becton Dickinson, Sparks, MD; 0.5% bacto-yeast extract, Becton 
Dickinson, Sparks, MD; and 1% NaCl, EMD Chemicals, Gibbstown, NJ; adjust PH to 
7.0 with 5 M NaOH and autoclave before use) in a 15 ml cultural tube.  
b. Incubate the culture at 37oC with vigorous shaking overnight.  
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c. Transfer 400 μl of this culture into 40 ml of LB media in a 250 ml flask and incubate 
the culture at 37oC with vigorous shaking for approximately one and half hours.  
d. Transfer the culture into a 40 ml centrifuge tube and centrifuge at 3,000 g for 3 min at 
4oC. Decant the supernatant and resuspend the pellet in 20 ml of ice cold autoclaved 
0.1 M CaCl2 (EMD Chemicals, Gibbstown, NJ). 
e. Keep the resuspended solution on ice for 30 minutes and then centrifuge at 3,000g for 
3 min at 4oC.  
f. Decant the supernatant and resuspend the pellet in 3 ml of ice cold 0.1 M CaCl2. Keep 
the cell solution at 4oC overnight. Add 1.5 ml of 50% glycerol into the cell solution, 
mix well and then aliquot 200 μl in each 1.5 ml Eppendorf tube stored at -70oC for 
later use.  
 
2.1.3 Cell Culture 
Human embryonic kidney (HEK) 293 cells (American Type Culture Collection, 
ATCC) were incubated at 37oC in a humidified atmosphere (containing 5% CO2) and 
grown in Dulbecco’s modified Eagle’s medium (DMEM, Gibco BRL) supplemented with 
10% heat-inactivated horse serum (Gibco BRL), 25 units/ml penicillin and 25 units/ml 
streptomycin (Gibco BRL). 
Rat phaeochromocytoma (PC12) cells (ATCC) were grown in DMEM with 10% 
heat-inactivated horse serum, 5% fetal bovine serum (Gibco BRL), 25 units/ml penicillin 
and 25 units/ml streptomycin. Culture plates and flasks were coated with rat-tail collagen 
(BD Biosciences, Bedford, MA). Cell cultures were maintained at 37oC with 5% CO2.  
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2.1.4 Animals 
    All procedures involving animals as well as the maintenance of the animals were 
executed with the approval of the University of Saskatchewan Animal Care and Use             
Committee (University of Saskatchewan Protocol# 20040034) and followed the guidelines 
from the Canadian Council on Animal Care and the National Institute of Health. The 
inbred adult (350~400 g body weight) male Long Evans rats were housed at a constant 
temperature on a 12-hr light/dark cycle, with free access to food and water.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 46
2.2 Methods 
 
2.2.1 Dissection of Rat Brain 
    In accordance with a protocol approved by the University of Saskatchewan Animal 
Care and Use Committee, rats were anaesthetized with sodium pentobarbital (65 mg/kg 
body weight) and killed by rapid decapitation. Rat brains were then quickly removed and 
the hippocampus and striatum were immediately dissected. Half of hippocampus was used 
immediately for the isolation of total RNA. The other brain samples were stored at -70oC 
for later use. 
 
2.2.2 Isolation of Total RNA 
    The following procedures were used to extract the total RNA from the rat brain tissue 
or mammalian cells.  
   a. Add 1.0 ml of TRIzol (Invitrogen, Burlington, ON) into a centrifuge tube containing 
100 mg of rat hippocampus tissue (or cell pellet) and homogenize the tissue with a 
homogenizer until the sample is uniformly dissociated.   
  b. Add 0.2 ml of chloroform (Sigma, St.Louis, MO) into the homogenized sample. 
Shake vigorously for 15 seconds and incubate for 2 minutes at room temperature. 
Centrifuge the sample at 12,000 g for 15 minutes at 4oC. 
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  c. Carefully transfer the colourless, upper aqueous phase (approximately 0.6 ml) 
containing the RNA into a clean microcentrifuge tube, avoiding removal of the 
material collected at the interface.  
d. Add 0.5 ml of isopropanol (Sigma, St.Louis, MO) into the aqueous phase and gently 
mix the solution well. Allow the RNA to precipitate at room temperature for 10 
minutes and then centrifuge at 12,000 g for 10 minutes at 4oC. 
e. Remove the supernatant and wash the RNA pellet once with 1.0 ml of 75% ethanol (in 
DEPC-treated water). Mix the sample by vortexing and centrifuge at 7500 g for 5 
minutes at 4oC to make sure that the pellet has sedimented before the ethanol is totally 
removed.  
f. Allow the RNA to dry for 10 minutes at room temperature and then dissolve the pellet 
with 50 μl of DEPC-treated H2O adding 1.0 μl of the RNasin Ribonuclease Inhibitor 
(Promega, Madison, WI). Store the total RNA at -70oC. 
 
2.2.3 RT-PCR 
Reverse transcription-polymerase chain reaction (RT-PCR) is a modification of 
polymerase chain reaction (PCR). The RNA strand, which is isolated from the tissue or 
cells, is first applied for reverse transcription into its complementary DNA (cDNA), 
followed by the amplification of the resulting DNA using PCR with specific primers. 
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2.2.3.1 Reverse Transcription of cDNA 
    To obtain the double-strand cDNA for PCR, reverse transcription with the above total 
RNA isolated from the rat hippocampus tissue was performed according to the following 
procedures. The total volume of reactive solution was 40 μl. 
  a. Add and mix the components as below to a 0.5 ml microcentrifuge tube: 
20 μl   Total RNA  
2 μl   Oligo(dT)20 Primer (Invitrogen, 50 μM)  
4 μl   dNTP mix (Promega, 10 mM each dATP, dTTP, dCTP, dGTP) 
b. Incubate the mixture at 65oC for 5 minutes and then put on ice. 
c. Collect the contents on the bottom of the tube by brief centrifugation and add: 
       8 μl   5× cDNA Synthesis Buffer (Invitrogen) 
       2 μl   0.1 M DTT (dithiothreitol)   
         2 μl   RNasin Ribonuclease Inhibitor (Promega, 40 units/μl) 
         2 μl   Cloned AMV Reverse Transcriptase (Invitrogen, 15 units/μl) 
  d. Mix the contents gently and incubate at 45oC for 60 minutes. 
  e. Heat the mixture at 85oC for 5 minutes to terminate the reaction and store the cDNA at 
-20oC. 
 
2.2.3.2 Primer Preparation for PCR 
The DNA sequences of the CB1 and D2 receptors were found from the Genbank.  
CB1: accession number NM_012784, 1419bp from 153 to 1571 (Figure 2.6); D2: 
accession number NM_012547, 1332bp from 347 to 1678 (Figure 2.7). The genes of the 
following fragments were prepared by RT-PCR for cloning: full length CB1 receptor (Full 
CB1, 473aa), CB1 extracellular N-terminal (CB1-NT, 1~117aa), CB1 intracellular loop3 
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(CB1-IL3, 301~345aa) and C-terminal (CB1-CT, 401~473aa), full length long form D2 
receptor (Full D2(L), 444aa), D2 intracellular loop3 (D2-IL3, 211~374aa) and five 
fragments of the D2 intracellular loop3 (D2-IL3 Ⅰ/Ⅱ/Ⅲ/Ⅳ/Ⅴ) (Figure 2.7).  
The open reading frames of these fragments were amplified from cDNA obtained 
from the reverse transcription of the rat hippocampal total RNA using the PCR with 
specific primers. All the primers (Figure 2.8, Figure 2.9) were synthesized by Invitrogen 
(Burlington, ON) and flanked by special restriction enzyme sites for the cloning of the 
amplified DNA sequences. Except for the full length D2 receptor that includes one 
“BamHI” restriction sites in its DNA sequence, all the fragments were flanked by 
“BamHI” & “EcoRI” for subcloning. Two different PCR products of the full length D2 
receptor were flanked by “EcoRI” & “XhoI” (including “TGA”) for subcloning into 
pGEX-6P-1 and pET-28a(+) vectors or flanked by “HindIII” & “EcoRI” (no “TGA”) for 
subcloning into pcDNATM3.1 vectors. There were also two different PCR products of the 
full length CB1 receptor. Both of them were incorporated with “BamHI” & “EcoRI”, but 
one included the stop code “TGA” and another did not.  
All the synthesized primers were prepared with autoclaved distilled water to a final 
concentration of 10 μM before use and stored at -20oC. 
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    1 ttaggtcgtt aggagaactt actgtgaaca ggctctttta tttcttcaaa agatgtctcc 
  61 catttcaagc aaggagcacc catggctgag ggttccctcc cggcatctct ttctcagtca 
 121 ccttgagtct ggcctaatca aagactgagg ttatgaagtc gatcctagat ggccttgcag 
 181 acaccacctt ccgtaccatc accacagacc tcctctacgt gggctcgaat gacattcagt 
 241 atgaagatat caaaggagac atggcatcca aattaggata cttcccacag aaattccctc 
 301 taacttcctt caggggtagt cccttccaag aaaagatgac cgcaggagac aactccccgt 
 361 tggtcccagc aggagacaca acaaacatta cagagttcta taacaagtct ctctcgtcgt 
 421 tcaaggagaa tgaggagaac atccagtgtg gggagaactt tatggacatg gagtgcttta 
 481 tgattctgaa tcccagccag cagctggcca tcgctgtact gtccctcaca ctgggcacct 
 541 tcacggttct ggagaaccta ctggtgctgt gtgtcatcct gcactcccgc agtctccgat 
 601 gcaggccttc ctaccacttc atcggcagcc tggcagtggc cgacctcctg ggaagtgtca 
 661 tttttgtgta cagctttgtt gacttccatg tattccaccg taaagacagc cccaatgtgt 
 721 ttctgttcaa actgggtggg gttacagcct ccttcacagc ttctgtgggc agcctgttcc 
 781 tcacagccat cgacaggtac atatccattc acaggcctct ggcctataag aggatcgtca 
 841 ccaggcccaa ggccgttgtg gccttttgcc tgatgtggac tatcgcaata gtaatcgctg 
 901 tgttgcctct cctgggctgg aactgcaaga agctgcaatc tgtttgctcg gacattttcc 
 961 cactcattga cgagacctac ctgatgttct ggattggggt gaccagtgtg ctgctgctgt 
1021 tcattgtgta cgcgtacatg tacattctct ggaaggctca cagccacgcg gtccgcatga 
1081 ttcagcgtgg gacccagaag agcatcatca tccacacgtc agaagacggc aaggtgcagg 
1141 tgacccggcc tgaccaagcc cgcatggaca ttaggctggc caaaaccctg gttctgatcc 
1201 tggtggtgtt gatcatctgc tggggccctc tgcttgcgat catggtgtat gacgtcttcg 
1261 ggaagatgaa caagcttatc aagacggtgt ttgccttctg cagtatgctc tgcctgctga 
1321 actccaccgt gaaccccatc atctatgctc tgaggagcaa ggacctgaga catgctttcc 
1381 gaagcatgtt cccttcgtgc gaaggcaccg cacagcctct agacaacagc atgggggact 
1441 cagactgcct gcacaagcac gccaacaaca cagccagcat gcacagggcc gcggagagct 
1501 gcatcaagag caccgttaag atcgcgaagg tgaccatgtc tgtgtccaca gacacgtccg 
1561 ccgaggctct gtgagcctgc tgcttttgtg gc 
 
 
Figure 2.6: The DNA sequence of the CB1 receptor was found from the Genbank: 
accession number NM_012784, 1419bp from 153 to 1571. The shading sequences 
are seven transmembrane domains; the italic sequences are four extracellular 
domains (CB1-NT/EL1/EL2/EL3); and the underlined sequences are four 
intracellular domains (CB1-IL1/IL2/IL3/CT). 
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 1 ctggtcgcct cttgtgcgca cgcctcctgc ccgccttccc gcctggtccc cgcgctgcgc 
    61 tcccgtcctc ccgccccgcc tcgtcctgcc ccgccgcggc cggtctactg ctccccgcgg 
   121 gcccgagccg gccgagcggc tgcccgccgg ggatctgaac gagtcatgcg gcggggccgg 
   181 aagccgaggg acccgcggag gggaccggcg gccccggacg gctgccggag gggcggccgt 
   241 gcgtggatgc ggcgggagct ggaagcctcg agcagccggc gccttctctg gccccgggcg 
   301 ccatatggct tgaagagccg tgccacccag tggccccact gccccaatgg atccactgaa 
   361 cctgtcctgg tacgatgacg atctggagag gcagaactgg agccggccct tcaatgggtc 
   421 agaagggaag gcagacaggc cccactacaa ctactatgcc atgctgctca ccctcctcat 
   481 ctttatcatc gtctttggca atgtgctggt gtgcatggct gtatcccgag agaaggcttt 
   541 gcagaccacc accaactact tgatagtcag ccttgctgtg gctgatcttc tggtggccac 
   601 actggtaatg ccgtgggttg tctacctgga ggtggtgggt gagtggaaat tcagcaggat 
   661 tcactgtgac atctttgtca ctctggatgt catgatgtgc acagcaagca tcctgaacct 
   721 gtgtgccatc agcattgaca ggtacacagc tgtggcaatg cccatgctgt ataacacacg 
   781 ctacagctcc aagcgccgag ttactgtcat gattgccatt gtctgggtcc tgtccttcac 
   841 catctcctgc ccactgctct tcggactcaa caatacagac cagaatgagt gtatcattgc 
   901 caaccctgcc tttgtggtct actcctccat tgtctcattc tacgtgccct tcatcgtcac 
   961 tctgctggtc tatatcaaaa tctacatcgt cctccggaag cgccggaagc gggtcaacac 
  1021 caagcgcagc agtcgagctt tcagagccaa cctgaagaca ccactcaagg gcaactgtac 
  1081 ccaccctgag gacatgaaac tctgcaccgt tatcatgaag tctaatggga gtttcccagt 
  1141 gaacaggcgg agaatggatg ctgcccgccg agctcaggag ctggaaatgg agatgctgtc 
  1201 aagcaccagt cccccagaga ggacccggta tagccccatc cctcccagtc accaccagct 
  1261 cactctccct gatccatccc accacggcct acatagcaac cctgacagtc ctgccaaacc 
  1321 agagaagaat gggcacgcca agattgtcaa tcccaggatt gccaagttct ttgagatcca 
  1381 gaccatgccc aatggcaaaa cccggacctc ccttaagacg atgagccgca gaaagctctc 
  1441 ccagcagaag gagaagaaag ccactcagat gcttgccatt gttctcggtg tgttcatcat 
  1501 ctgctggctg cccttcttca tcacgcacat cctgaatata cactgtgatt gcaacatccc 
  1561 accagtcctc tacagcgcct tcacatggct gggctatgtc aacagtgccg tcaaccccat 
  1621 catctacacc accttcaaca tcgagttccg caaggccttc atgaagatct tgcactgctg 
  1681 agtctgcccc ttgcctgcac agcagctgct tcccacctcc ctgcctatgc aggccagacc 
 
 
Figure 2.7: The DNA sequence of the D2 receptor was found from the Genbank: accession 
number NM_012547, 1332bp from 347 to 1678. The boxed sequence is the 
“BamHI” restriction site. The underlined sequences are four intracellular domains 
(D2-IL1/IL2/IL3/CT). The light shading sequences with underline are the three 
fragments (Ⅰ: 11~241aa, Ⅲ: 271~305aa, Ⅴ: 341~374aa) and the dark shading 
sequences with underline are the other two fragments (Ⅱ: 242~270aa, Ⅳ: 
306~340aa) of the D2 intracellular loop3. 
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Figure 2.8: Primers for CB1 receptor fragments prepared by RT-PCR and flanked by 
“BamHI” & “EcoRI” restriction sites (marked by underline) for cloning.  
      F(forward): sense primer        R(reverse): anti-sense primer 
          BamHI (5´-G↓GATCC-3´)      EcoRI (5´-G↓AATTC-3´) 
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Figure 2.9: Primers for D2 receptor fragments produced by RT-PCR and flanked by 
“BamHI” & “EcoRI”, “EcoRI” & “XhoI” or “HindIII” & “EcoRI” restriction sites 
(marked by underline) for cloning.  
      F(forward): sense primer        R(reverse): anti-sense primer 
          BamHI (5´-G↓GATCC-3´)      EcoRI (5´-G↓AATTC-3´) 
          XhoI (5´-C↓TCGAG-3´)        HindIII (5´-A↓AGCTT-3´)  
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2.2.3.3 PCR Experiments 
The following “hot-start” PCR protocol (with total volume 50 μl as an example) 
served as a general guideline for our PCR experiments. Optimal reaction conditions  
(i.e. total volumes of reactions, primers, different kinds or concentrations of DNA 
polymerase, incubation temperatures and times, template DNA as well as MgCl2) varied 
and were optimized for each DNA fragment. 
a. Add and mix the following components to a sterile 0.2 ml microcentrifuge tube: 
     5 μl   10× PCR buffer (include MgCl2)  
     4 μl   dNTP mixture (Promega, 2.5 mM each dATP, dTTP, dCTP, dGTP) 
     5 μl   10 μM Sense primer 
     5 μl   10 μM Anti-sense primer 
     1 μl   Template cDNA 
    20 μl   Autoclaved distilled water 
  b. Cap the tube and centrifuge briefly to collect the contents on the tube bottom. Put the 
sample in the PCR equipment and incubate it at 94oC for 2 minutes to completely 
denature the template. 
  c. After denaturation at 94oC, add 2~5 units of Taq (New England Biolabs, Ipswich, 
MA), Vent (New England Biolabs, Ipswich, MA) or Pfu (Fermentas, Burlington, ON) 
DNA polymerase in 10 μl autoclaved distilled water. 
  d. Perform 28~35 cycles of PCR amplification as follows: 
         Denature     94oC for 40 seconds 
         Anneal       55oC~60oC for 30 or 40 seconds 
         Extend       72oC for 1 minute or 1 minute 30 seconds 
  e. Incubate the sample at 72oC for an additional 10 minutes and maintain the reaction at 
4oC. The sample could be stored at -20oC until use. 
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  f. Visualize the amplification products by agarose (Invitrogen, Burlington, ON) gel 
electrophoresis with ethidium bromide (EtBr) and DNA molecular weight standards. 
  g. Purification of the amplified DNA products from the agarose gel was performed by 
using Gel and PCR Clean-Up Kit (Promega, Madison, WI) according to 
manufacturer’s protocol.   
 
2.2.4 Synthesis Fragments 
The appropriate complementary single-stranded DNA oligos of the mini-genes of the 
CB1 and D2 receptor short fragments less than 30 amino acids were directly synthesized by 
“Invitrogen”. Each sequence was designed to give sticky ends, using “BamHI” & “EcoRI” 
restriction sites, to allow insertion into the pGEX-2T vector.  
    The following procedures were employed to generate the double-stranded DNA 
fragments by annealing the synthesized complementary single-stranded DNA oligos. 
  a. Resuspend the lyophilized single-stranded oligos in distilled water to a final 
concentration of 200 μM before use. Prepare 10× Oligo Annealing Buffer (100 mM 
Tris-HCl, J.T.Baker, Phillipsburg, NJ, PH 8.0; 10 mM EDTA, Sigma, St.Louis, MO, 
PH 8.0; and 1 M NaCl) for use.  
  b. Add the components as follows in a 0.5 ml sterile microcentrifuge tube to set up the 
annealing reaction at room temperature (total volume 20 μl). 
5 μl    200 μM “Sense strand” DNA oligo 
            5 μl    200 μM “Anti-sense strand” DNA oligo 
            2 μl    10× Oligo Annealing Buffer   
            8 μl    DNase/RNase-free Water 
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 c. Incubate the sample at 95oC for 4 minutes. Remove the tube containing the annealing 
reaction from water bath and allow the reaction mixture to cool to room temperature 
for 5~10 minutes, during which single-stranded oligos anneal. 
  d. Centrifuge the annealing mixture for 3~5 seconds and mix gently. The concentration 
of the double-stranded DNA oligo is 50 μM. 
  e. Dilute 1 μl of the 50 μM double-stranded DNA oligo mixture into 99 μl of 
DNase/RNase-free water to obtain a final concentration of 500 nM and vortex to mix 
thoroughly. 
  f. Dilute 1 μl of the 500 nM double-stranded DNA oligo mixture into 99 μl of 1× Oligo 
Annealing Buffer as follows to obtain a final concentration of 5 nM and vortex to mix 
thoroughly.    
1 μl    500 nM double-stranded DNA oligo 
10 μl    10× Oligo Annealing Buffer 
89 μl    DNase/RNase-free Water 
  g. Aliquot the 5 nM double-stranded DNA oligo stock for subcloning. Store the 
remainder of the 50 μM, 500 nM and 5 nM double-stranded DNA oligos at -20oC.  
The DNA sequences of these synthetic fragments, which include CB1 intracellular 
loop1, 2 and extracellular loop1, 2, 3 (CB1-IL1/IL2/EL1/EL2/EL3), D2 intracellular loop1, 
2 and C-terminal (D2-IL1/IL2/CT) and three motifs of the fourth fragment of the D2 
intracellular loop3 (D2-IL3 Ⅳ1/2/3), were listed as follows (all sequences with 
5´-3´direction, F: sense, R: anti-sense).  
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CB1-IL1 (144~155aa/36bp)  
F: GATCCCACTCCCGCAGTCTCCGATGCAGGCCTTCCTACCACTGAG 
R: AATTCTCAGTGGTAGGAAGGCCTGCATCGGAGACTGCGGGAGTGG  
CB1-IL2 (214~233aa/60bp) 
F: GATCCGACAGGTACATATCCATTCACAGGCCTCTGGCCTATAAGAGGATC 
GTCACCAGGCCCAAGTGAG 
R: AATTCTCACTTGGGCCTGGTGACGATCCTCTTATAGGCCAGAGGCCTGTG 
AATGGATATGTACCTGTCG  
CB1-EL1 (177~188aa/36bp) 
F: GATCCGACTTCCATGTATTCCACCGTAAAGACAGCCCCAATTGAG 
R: AATTCTCAATTGGGGCTGTCTTTACGGTGGAATACATGGAAGTCG  
CB1-EL2 (257~274aa/54bp) 
F: GATCCAACTGCAAGAAGCTGCAATCTGTTTGCTCGGACATTTTCCCACTC 
ATTGACGAGTGAG 
R: AATTCTCACTCGTCAATGAGTGGGAAAATGTCCGAGCAAACAGATTGCA 
GCTTCTTGCAGTTG  
CB1-EL3 (367~378aa/36bp) 
F: GATCCGACGTCTTCGGGAAGATGAACAAGCTTATCAAGACGTGAG 
R: AATTCTCACGTCTTGATAAGCTTGTTCATCTTCCCGAAGACGTCG  
D2-IL1 (60~70aa/33bp)  
F: GATCCTCCCGAGAGAAGGCTTTGCAGACCACCACCAACTGAG 
R: AATTCTCAGTTGGTGGTGGTCTGCAAAGCCTTCTCTCGGGAG 
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D2-IL2 (131~151aa/63bp) 
F: GATCCGACAGGTACACAGCTGTGGCAATGCCCATGCTGTATAACACACGC 
TACAGCTCCAAGCGCCGATGAG 
R: AATTCTCATCGGCGCTTGGAGCTGTAGCGTGTGTTATACAGCATGGGCATT 
GCCACAGCTGTGTACCTGTCG 
D2-CT (431~444aa/42bp) 
F:GATCCAACATCGAGTTCCGCAAGGCCTTCATGAAGATCTTGCACTGCTGAG 
R:AATTCTCAGCAGTGCAAGATCTTCATGAAGGCCTTGCGGAACTCGATGTTG 
D2-IL3 (IV1) (306~317aa /36bp) 
F: GATCCACTCTCCCTGATCCATCCCACCACGGCCTACATAGCTGAG 
R: AATTCTCAGCTATGTAGGCCGTGGTGGGATGGATCAGGGAGAGTG 
D2-IL3 (IV2) (318~329aa/36bp) 
F: GATCCAACCCTGACAGTCCTGCCAAACCAGAGAAGAATGGGTGAG 
R: AATTCTCACCCATTCTTCTCTGGTTTGGCAGGACTGTCAGGGTTG 
D2-IL3 (IV3) (330~340aa/33bp) 
F: GATCCCACGCCAAGATTGTCAATCCCAGGATTGCCAAGTGAG 
R: AATTCTCACTTGGCAATCCTGGGATTGACAATCCTGGCGTGG 
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2.2.5 Cloning and Subcloning 
    DNA fragments from RT-PCR or direct synthesis were cloned and subcloned into 
specific vectors to get recombinant plasmids by ligation after the digestion of DNA 
fragments and vectors with appropriate restriction enzymes (all enzymes from Fermentas, 
Burlington, ON). Ligation is a process by which two DNA fragments, a small DNA insert 
containing target DNA and a plasmid vector, are combined together by using T4 DNA 
ligase (Fermentas, Burlington, ON). 
    All the DNA fragments described previously, except for the full length D2 receptor, 
were cloned into pGEX-2T vector to get the GST fusion proteins in E.coli cells. The 
pGEX-2T vectors and the fragments produced by RT-PCR were digested with “BamHI” & 
“EcoRI” restriction enzymes to obtain sticky ends for ligation. The synthesized and then 
annealed double-stranded DNA fragments with the blunt ends could be directly inserted 
into the digested pGEX-2T vectors. The full length D2 receptor was cleaved with “EcoRI” 
& “XhoI” restriction enzymes and then ligated into pGEX-6P-1 and pET-28a(+) vectors for 
expressing its fusion proteins with GST or 6His. The full length CB1 receptor was also 
subcloned into pGEX-6P-1 and pET-28a(+) vectors with “BamHI” & “EcoRI” restriction 
sites. To over-express the full length CB1 and D2 receptors and their “-myc” or “-FLAG” 
tagged recombinant proteins in mammalian cells, their gene coding sequences were 
inserted into pcDNATM3.1 vectors. For this subcloning, the DNA fragments of the full 
length D2 and CB1 receptors were respectively digested with “HindIII” & “EcoRI” and 
“BamHI” & “EcoRI” restriction enzymes. As to the digestion, the reaction was allowed to 
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incubate at 37℃ for 2~3 hours whereas the reaction of the ligation was incubated at 22℃ 
for 2 hours or at 4℃ overnight. 
After cloning and subcloning, the ligation reactions were transformed into DH5α 
competent E.coli cells to select the correct insert-containing clones of each recombinant 
plasmid for sequencing. 
 
2.2.6 Transformation  
   Bacterial transformation is a process to introduce a foreign plasmid into bacterial cells 
and to use the bacteria for amplification of this plasmid. The procedure of transformation 
includes the following steps.  
a. Remove competent E.coli cells from -70oC freezer and place directly on ice to thaw 
out for 5~10 minutes.  
b. Add 20 μl of the ligation reaction of one recombinant plasmid or 1 μl of selected 
plasmid into the competent cells and allow sitting on ice for 30 minutes.  
c. Place the mixture in a 42oC water bath for exactly 90 seconds and immediately return 
to ice for 5 minutes.  
d. Incubate the mixture with 600 μl of LB media at 37oC for 45 minutes and then 
centrifuge at 5000 g for 5 minutes. Decant most of supernatant leaving the cells to be 
resuspended in approximately 100 μl of media.  
e. Spread the cells on a LB-agar plate containing the appropriate selection components 
and allow the transformed cells to grow overnight in a 37oC incubator. The use of 
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special blue-white screening with IPTG (isopropylthio-β-galactoside, Promega, 
Madison, WI) and X-GAL (5-bromo-4-chloro-3-indolyl-β-galactoside, Promega, 
Madison, WI) was applied for the recombinant plasmids fused with DNA insert and 
the pGEM-T Easy vector. 
 
2.2.7 Plasmid Purification and Identification 
    A single clone from a freshly grown LB-agar plate of E. coli cells transformed with 
the recombinant plasmid was cultured in 5 ml of LB media with appropriate antibiotics in a 
15ml cultural tube for incubation at 37oC with vigorous shaking. The mini-prep procedure 
of plasmid DNA purification was then performed with the overnight cultures to isolate 
plasmid DNA using the manufacturer's protocol (Promega, Madison, WI).  
    Two methods were applied for the identification of the recombinant plasmids: 
restriction digestion and inducing expression. In total, 13 PCR products were cloned and 
subcloned into different vectors and then identified with restriction digestion. Eleven 
synthetic fragments were ligated into pGEX-2T vector and then identified by inducing 
expression.  
    Samples of purified plasmid DNA were digested using appropriate restriction 
enzymes incubated at 37oC for 2~3 hours to see if the insert was present within the vector. 
The digestion reaction was run on a 1% agarose gel with EtBr to visualize the cleaved 
DNA, which was compared to a DNA ladder of known band sizes. Once the appropriate 
DNA insert was visualized, the sample was prepared for sequencing. (Examples as Figure 
2.10) 
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For inducing expression, the overnight culture described above was 1:100 sub-cultured 
into 5 ml of LB media adding ampicillin (100 μg/ml, Sigma, St.Louis, MO) at 37°C with 
vigorous shaking for 1.5 hours. The culture, cooled down to room temperature, was then 
treated with IPTG at a final concentration of 1.0 mM to induce protein expression and 
allowed to grow an additional 3~4 hours at 26°C in an orbital shaker. A pellet, obtained by 
centrifuging 500 μl of the culture at 5000 g for 5 minutes, was boiled for 10 minutes with an 
equivalent volume of 2× SDS sample buffer (50 mM Tris-HCl, PH 6.8; 4% SDS, Sigma; 
50 mM DTT, Sigma; 20% Glycerol, Sigma; and 0.2% Bromophenol Blue, Sigma, St.Louis, 
MO). After centrifuging the boiled sample at 12,000 g for 10 minutes, 5~10 μl supernatant 
of the sample was loaded into SDS-PAGE gel for protein staining and destaining (see 
Section 2.2.9) to make sure if the fusion protein was expressed. One clone showing the 
inducing expressed fusion protein would be sent for sequencing. (Examples as Figure 2.11) 
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Figure 2.10: Two clones of each recombinant plasmid of “CB1-IL3 in pGEX-2T” and 
“CB1-CT in pGEX-2T” were identified by restriction digestion with “BamHI” & 
“EcoRI” restriction enzymes. “CB1-IL3” (135bp) and “CB1-CT” (219bp) were 
found to be successfully inserted into pGEX-2T vector in their samples.  
      (M: DNA ladder) 
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Figure 2.11: Five clones of each recombinant plasmid of “D2-IL1 in pGEX-2T” and 
“D2-CT in pGEX-2T” and two clones of another recombinant plasmid “D2-IL2 in 
pGEX-2T” were identified by IPTG inducing expression. Expressed GST protein 
(GST: 26KDa) and non-inducing expression sample (control) were applied as 
controls. Results showed that all the clones had been induced to express their own 
fusion proteins (GST-D2-IL1: 27KDa, GST-D2-CT: 27.5KDa, GST-D2-IL2: 
28KDa), suggesting that these three DNA fragments were successfully ligated into 
pGEX-2T vector. 
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2.2.8 Sequencing 
    To confirm correct splice fusion without spurious PCR-generated errors, one 
appropriate clone for each recombinant plasmid was screened out through “restriction 
digestion” or “inducing expression” and sent to PBI (Plant Biotechnology Institute) for 
sequencing. Different primers were applied for forward and reverse sequencing of DNA 
fragments in diverse vectors as follows.  
    pGEX-2T Vector:      5´pGEX Sequencing Primer 
                        3´pGEX Sequencing Primer 
    pET-28a(+) Vector::    T7 Promoter Sequencing Primer 
T7 Terminator Sequencing Primer 
    pcDNATM3.1 Vectors:  T7 Promoter Sequencing Primer 
                        BGH Reverse Sequencing Primer 
    pGEM-T Easy Vector:  pUC/M13 Forward Sequencing Primer   
                        pUC/M13 Reverse Sequencing Primer 
 
2.2.9 Protein Staining and Destaining 
After loaded into SDS-PAGE gel, proteins were visualized by Coomassie Blue 
staining and destaining and then compared to protein standards. Staining was accomplished 
by soaking the gel in the stain solution (45% methanol, EMD Chemicals, Gibbstown, NJ; 
10% acetic acid, BDH Chemicals, Toronto, ON; 0.25% Coomassie Blue R-250, EM 
Science, Gibbstown, NJ; and 45% deionized water) on a shaker for 30 minutes or overnight 
at room temperature. A quick staining could be performed by heating the stain/gel in a 
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microwave oven for ~10 seconds until the solution was sufficiently warm but did not boil, 
then shaking for ~10 minutes.  
To destain gel, the gel was removed from the stain solution and soaked in the destain 
solution (30% methanol, 10% acetic acid and 60% deionized water) with gentle shaking 
overnight at room temperature. Also, a quick destaining was carried out by microwaving 
the destain/gel for 10 seconds (heating could be repeated) until sufficiently warm (did not 
boil), and letting stand with gentle shaking. Periodically replace with the fresh destain 
solution until desired destaining was achieved.   
 
2.2.10 Over-Expression of Fusion Proteins in E.coli Cells 
Each recombinant plasmid was sequenced to confirm the correct DNA insert sequence 
and then transformed into an appropriate strain of competent E.coli cells to over-express 
fusion proteins by inducing with IPTG. As mentioned previously, transformation of BL21 
competent cells was applied for the over-expression of GST fusion proteins whereas 
transformation of DE3 competent cells was employed to over-express 6His fusion proteins. 
    The procedures of IPTG inducing over-expression of fusion proteins in E.coli cells are 
listed below. 
  a. Pick a single clone from a freshly cultured LB-agar plate of E. coli cells transformed 
with the sequenced recombinant plasmid and disperse it in 3~5 ml of LB media with 
appropriate antibiotics (ampicillin, Sigma, St.Louis, MO; or kanamycin, EMD 
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Chemicals, Gibbstown, NJ) in a 15ml cultural tube for incubation at 37oC overnight 
with vigorous shaking.   
  b. Sub-culture 400 μl of the overnight culture into 40 ml of LB media adding appropriate 
antibiotics in a 250 ml flask and incubate at 37°C with vigorous shaking for 1.5 hours.  
c. Cool down the above culture to room temperature and then induce with IPTG to a final 
concentration of 1.0 mM. Allow the cells to grow an additional 3~4 hours at 26°C in an 
orbital shaker. 
d. Take 500 μl of the culture for protein staining and destaining (see Section 2.2.7 for 
“inducing expression”) to confirm that the fusion protein was expressed in the E.coli 
cells. 
e. Transfer the culture into a 40 ml centrifuge tube and harvest the cells by centrifuging at 
3000 g for 3 minutes at 4°C. 
f. Resuspend and wash the cell pellet with 1 ml of ice cold 1× PBS buffer (150 mM NaCl, 
13 mM KCl, 10 mM Na2HPO4 and 1.7 mM NaH2PO4, PH 7.4, all chemicals from 
EMD Chemicals, Gibbstown, NJ). Transfer the resuspended cells to a 1.5 ml 
microcentrifuge tube and pellet the cells by centrifuging at 5000 g for 3 minutes. 
g. Pour off the supernatant and store the cell pellet at -20oC for later use. 
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2.2.11 Purification of Fusion Proteins 
    Glutathione Seqpharose 4B (Amersham Biosciences, Piscataway, NJ) and Ni-NTA 
His•Bind Resins (Novagen, Mississaga, ON) were applied for purification of GST and 6His 
fusion proteins, respectively. Glutathione Sepharose 4B (Glutathione immobilized on 
sepharose beads) is designed for the rapid and convenient single step purification of GST 
fusion proteins, recombinant derivatives of glutathione S-transferase. Ni-NTA His•Bind 
Resins contain metal(Ni2+)-chelating reactive nitrilotriacetic acid (NTA) groups covalently 
attached to a solid support and the immobilized Ni2+ has the remarkable affinity for a tag of 
six consecutive histidine residues (6His tag). Thereby, they are chosen to allow one-step 
purification of 6His-tagged proteins under native or denaturing condition.  
    Purification of GST or 6His fusion proteins was performed by the following 
procedures. 
a. Bacterial Cell Lysis (all steps should be done on ice)  
a) Add 500µl of ice cold “Bacterial cell lysis buffer” (50 mM Tris-HCl pH 8.0; 
0.25% Sodium Deoxycholate, Sigma, St.Louis, MO; 0.15 M NaCl; 1% Nonidet 
P40, EM Science, Gibbstown, NJ; and 1% Tritoon X-100, Sigma, St.Louis, MO) 
containing 1 µl (1:500) of protease inhibitors (for bacterial cells, Sigma, St.Louis, 
MO), 1.0 mM DTT and 0.5 mg/ml lysozyme (Sigma, St.Louis, MO) to the fresh 
or frozen cell pellet from 1ml of bacterial culture (as described in Section 2.2.10) 
in a 1.5 ml microcentrifuge tube.  
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b) Incubate the cell pellet on ice for approximately 30 minutes and resuspend by 
pipetting or gentle mixing every few minutes until the solution becomes clear; 
c) Further lyse cells with ultrasonic disruption (0.5-MHz ultrasound for 10 seconds × 
20 times) and centrifuge at 12,000 g for 10 minutes at 4°C to obtain the 
supernatant of the cell lysate.  
b. Preparation of Matrix 
a) Gently shake the bottle to resuspend the matrix of Glutathione Sepharose 4B or 
Ni-NTA His•Bind Resins and transfer sufficient slurry (20~30 µl) to a 1.5 ml 
microcentrifuge tube. 
b) Sediment the matrix by centrifuging at 5000 g for 30 seconds and then carefully 
remove the supernatant. 
c) Wash the matrix with 500 µl of ice cold “Bacterial cell lysis buffer” by inverting 
the tube several times to mix. 
d) Collect the matrix by centrifugation at 5000 g for 30 seconds and then carefully 
decant the supernatant. 
e)  Repeat matrix equilibration steps c) and d) twice for a total of 3 washes and 
gently resuspend the matrix in 50 µl of ice cold “Bacterial cell lysis buffer” after 
the final wash.  
c. Binding of Fusion Proteins 
a) Add the supernatant of the cell lysate, prepared as described above, to the 
equilibrated matrix and mix gently by pipetting or inverting. 
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b) Incubate the sample with gentle mixing on a rotating platform for 1 hour at 4°C 
for binding of fusion proteins. 
  d. Washing of Nonspecific Proteins (samples keep on ice) 
a) Pellet the matrix by centrifuging at 5000 g for 30 seconds and then carefully 
remove the supernatant.   
b) Add 800 µl of ice cold “Bacterial cell lysis buffer” to the matrix and mix gently 
by inverting the tube several times. 
c) Collect the matrix by centrifugation at 5000 g for 30 seconds and then carefully 
decant the supernatant. 
d) Repeat Washing Steps twice for a total of 3 washes and gently resuspend the 
matrix in 50 µl of ice cold “Bacterial cell lysis buffer” after the final wash. 
  e. Elution and Identification of Fusion Proteins 
a) Boil 10 µl of the above resuspended slurry for 10 minutes with 10 µl of 2× SDS 
sample buffer to elute the bound fusion proteins from the matrix.  
b) Load 5~10 μl supernatant of the boiled sample, centrifuged at 12,000 g for 10 
minutes, into SDS-PAGE gel for protein staining and destaining to visualize the 
purified fusion proteins in comparison with protein standards. 
c) Store the reminder of the resuspended slurry at 4°C for later use.  
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2.2.12 Expression of Proteins in Mammalian Cells 
High-level stable and non-replicative transient gene expression can be carried out in 
most mammalian cells through the transfection of the recombinant plasmids fused with 
gene DNA fragments and pcDNA™3.1 vectors. Here, two mammalian cell lines, HEK293 
cells and PC12 cells, were transfected with five recombinant plasmids, “CB1 in 
pcDNA™3.1/myc-His(B)”, “CB1 in pcDNA™3.1/FLAG(B)”, “CB1(TGA) in 
pcDNA™3.1/myc-His(B)”, “D2 in pcDNA™3.1/myc-His(B)”,” and “D2 in 
pcDNA™3.1/FLAG(B)”, to transiently express the full length CB1 and D2 receptors and 
their “-myc” or “-FLAG” tagged fusion proteins. 
To obtain sufficient plasmids for transfection, the sequenced correct recombinant 
plasmids were transformed into JM109 competent cells for amplification. After purification 
and quantitation, 50 μl of aliquot plasmid DNA were stored at -20°C for transfection. The 
following procedures were employed for transient transfection with LipofectamineTM 2000 
reagent (Invitrogen, Carlsbak, CA). 
a. Trypsinize with Trypsin-EDTA (Gibco, BRL) and plate the cells in 6-well plates 
(collagen-coated plates for PC12 cells) at 1 × 106 cells per well with 2~3 ml of their 
normal growth medium without antibiotics on the day before transfection. The cells 
would be 90~95% confluence on the day of transfection. 
b. Dilute 2~4 μg of DNA into 125~250 μl of DMEM and 5~10 μl of LipofectamineTM 
2000 into 125~250 μl of DMEM for each well of cells to be transfected and incubate the 
diluted LipofectamineTM 2000 at room temperature for 5 minutes. 
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  c. Mix the diluted DNA with the diluted LipofectamineTM 2000 (from the last step) and 
then incubate at room temperature for 20 minutes to form DNA-LipofectamineTM 2000 
complexes.  
  d. Add the DNA-LipofectamineTM 2000 complexes (250~500 μl) directly to each well and 
gently rock the plate back and forth to mix well. 
   e. Incubate the transfected cells in a 37oC incubator with 5% CO2 for 24~72 hours and 
then harvest the cells for analysis of transgene expression. For the well of cells to grow 
over 24 hours, replace the growth medium 6 hours after transfection. 
To identify transfection efficiency, one well of cells would be transfected with the 
plasmids containing the green fluorescent protein (GFP) as a control. GFP, which emits 
green light when excited by blue light, is a spontaneously fluorescent protein isolated from 
coelenterates. The intrinsic fluorescence of GFP can be visualized in living cells by 
fluorescence correlation microscopy 24 hours after transfection. Furthermore, RT-PCR (see 
Section 2.2.3) could be employed for the identification of efficient transfection. The total 
RNAs, extracted from non-transfected cells (as a negative control) and transfected cells 
with empty vectors (as another negative control) or recombinant plasmids, were applied for 
reverse transcription into their cDNAs, followed by the amplification of DNA fragments of 
the full length CB1 and D2 receptors using PCR with appropriate primers.  
The transfected cells were harvested from each well and centrifuged at 1000 g for 5 
minutes to remove the media. The cell pellet was then washed with ice cold 1× PBS buffer 
and lysed by appropriate volume of ice cold “Modified RIPA lysis buffer” (50 mM 
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Tris-HCl pH 7.4, 0.25% Sodium Deoxycholate, 0.15 M NaCl, 1% Nonidet P40 and 1.0 
mM EDTA) containing protease inhibitor (1:100 using for mammalian cells, Sigma, 
St.Louis, MO). The cell lysate was boiled for 10 minutes with an equivalent volume of 2× 
SDS sample buffer and centrifuged at 12,000g for 10 minutes. The supernatant would be 
loaded into SDS-PAGE gel for western blot to analyze if the transgenes were expressed in 
the transfected cells. 
 
2.2.13 Western Blot (Immunoblotting, IB) 
Western blot (Immunoblotting, IB), a technique for the analysis and identification of 
protein antigens, was performed by the following detailed procedures. Quantitation of total 
protein concentration was accomplished by the BCA Protein Assay Kit (Pierce, Rockford, 
IL) with protein standard—BSA (Bovine Serum Albumin) if necessary.  
a. Prepare SDS-PAGE gel consisting of 4% Stacking gel and 10% Resolving gel 
(volumes listed below for one piece gel of 0.75 mm thickness).         
10% Resolving gel (4 ml)        4% Stacking gel (1.5 ml) 
ddH2O       1.6 ml           ddH2O      0.86 ml                              
Buffer A      1 ml            Buffer C    0.375 ml 
30%AB      1.34 ml          30%AB     0.25 ml                 
10%APS      20 μl           10%APS    15 μl 
10%SDS      40 μl           10%SDS    15 μl    
TEMED       4 μl            TEMED     3 μl 
Buffer A: 1.5 M Tris-HCL, PH 8.8, 0.5% SDS                                         
Buffer C: 0.5 M Tris-HCL, PH 6.8, 0.5% SDS 
    (Except for ddH2O and 10% SDS, other solutions store at 4°C; 30% AB from 
    Bio-Rad, Hercules, CA; APS, SDS, and TEMED from Sigma, St.Louis, MO) 
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  b. Load up to 10~20 μl of prepared protein samples per well for gels of 0.75mm 
thickness and run gel in 1× Running buffer (25 mM Tris-HCl, 0.1% SDS and 250 
mM Glycine, ICN Biomedicals, Aurora, OH) at 120 V until bromophenol blue dye 
reaches bottom of gel.        
   c. Transfer the proteins from the gel to an Immuno-Blot PVDF membrane (Bio-Rad, 
Hercules, CA) in 1× Transfer buffer (25 mM Tris-HCl, 250 mM Glycine, 0.00375% 
SDS and 20% Methanol) at 0.2 A for 2~3 hours on ice.    
d. Briefly wash the membrane for 30 seconds in 1× TBST buffer (25 mM Tris-HCl, PH 
7.4, 150 mM NaCl and 0.1% Tween-20, Sigma, St.Louis, MO) and soak the 
membrane in 10~15ml “blocking solution” (5% instant skim milk in 1× TBST buffer) 
to cover the membrane for 30~60 minutes with gentle shaking at room temperature.  
e. Incubate the membrane in a primary antibody diluted with “blocking solution” for 2 
hours at room temperature or overnight at 4°C with gentle shaking and then rinse the 
membrane for 3×10 minutes in 1× TBST buffer at room temperature on a shaker. 
f. Incubate the membrane with the HRP-conjugated secondary antibody (1:2000~5000, 
diluted with “blocking solution”); gently shake at room temperature for 2~3 hours 
and then rinse the membrane with 1× TBST buffer for 5× 5 minutes at room 
temperature on a shaker. 
g. Incubate the membrane for 1 minute in ECLTM Western Blotting Detection Reagent 
(Amersham Biosciences, Piscataway, NJ) and expose to X-Ray film (KODAK, New 
Haven, Conn.) for variable exposure times. Develop the film to visualize proteins.  
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h. Re-expose the membrane, if required. Strip the membrane with 1× stripping buffer 
(65 mM Tris-HCl, PH 6.8, 2% SDS and 100 mM β-mercaptoethanol, Sigma, 
St.Louis, MO) for 1 hour at 60°C. Wash the stripped membrane for 3× 10 minutes in 
1× TBST buffer at room temperature on a shaker prior to blocking in 5% milk 
solution.  
 
2.2.14 Pull-Down Assay 
The pull-down assay is an in vitro affinity chromatography method used to confirm 
the existence of protein-protein interaction predicted by other research techniques and to 
identify previously unknown protein-protein interaction. In a pull-down assay, a tagged or 
labeled bait protein is used to create a specific affinity matrix that will be able to bind and 
purify prey proteins from a lysate sample, which interact with the bait protein. 
Two types of lysate samples were used in pull-down assays in this study. One type of 
lysate was prepared from the bacterial cells over-expressed GST or 6His fusion proteins 
(from Section 2.2.10 and preparation as Section 2.2.11.a). To avoid the false positive 
results produced by the contamination of the pull-down complexes through excessive 
concentrations of bacterial cell lysate, which dilution of bacterial cell lysate should be first 
decided for each pull-down assay. Another one was obtained by homogenizing rat striatum 
tissues (from Section 2.2.1) with homogenizer in ice cold “Modified RIPA lysis buffer” (3 
ml of buffer per gram of tissue kept on ice) until the sample was uniformly dissociated. The 
homogenized tissue lysate was frozen at -70°C until use. To obtain the supernatant, the 
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homogenized tissue lysate was centrifuged at 14,000g for 15 minutes at 4°C. The total 
protein concentration of lysate was quantified by the BCA Protein Assay Kit (Pierce, 
Rockford, IL) with protein standard (i.e. BSA). 
The lysate was incubated with purified GST or 6His fusion proteins immobilized on 
the matrix (from Section 2.2.11) at 4°C nutating overnight. The beads were washed five 
times with 800 μl of ice cold lysis buffer and then centrifuged at 5000 g for 30 seconds. 
Eventually, the bound (prey) proteins were eluted by boiling for 10 minutes with an 
equivalent volume of 2× SDS sample buffer and analyzed by western blot (see Section 
2.2.13). The GST protein was always employed as a negative control for all the pull-down 
assays in present study. 
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3  RESULTS 
 
3.1 RT-PCR Reactions for Generation of CB1 Receptor and D2 Receptor 
Fragments  
 
3.1.1 PCR-based Amplification of CB1 Receptor Fragments 
    The DNA sequences of five longer fragments (over 90 bp) of the CB1 receptor, two 
full length CB1 (CB1 and CB1-TGA) and CB1-NT/CT/IL3, were amplified by RT-PCR 
with the cDNA from the rat hippocampal tissue and their specific sense and anti-sense 
primers.  
    The full length CB1 fragments (1419 bp, Figure 3.1) were obtained by the 
performance of 35 cycles of PCR amplification with a denaturation temperature of 94℃ for 
40 seconds, an annealing temperature of 55℃ for 40 seconds and an extension temperature 
of 72℃ for 90 seconds, using Vent DNA polymerase, a high-fidelity thermophilic DNA 
polymerase. After the full length CB1 was successfully amplified, the same DNA template 
was used to amplify the other three CB1 fragments, i.e. CB1-NT (351 bp, Figure 3.1), 
CB1-CT (219 bp, Figure 3.2) and CB1-IL3 (135 bp, Figure 3.2). These PCR amplifications 
were performed for 28 cycles with an annealing temperature of 60℃ for 40 seconds and an 
extension time of 60 seconds, using pfu DNA polymerase, which was applied for 
high-fidelity PCR.       
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Figure 3.1: PCR products of the full length CB1 receptor (1419 bp) and CB1-NT  
    (351 bp), electrophoresed on a 1% agarose gel and visualized with ethidium  
  bromide (EtBr). 
 
 
 
   
 
Figure 3.2: PCR products of CB1-CT (219 bp) and CB1-IL3 (135 bp), electrophoresed on 
a 1% agarose gel and visualized with EtBr. 
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3.1.2 PCR-based Amplification of D2 Receptor Fragments 
    In the same way, RT-PCR was employed to amplify DNA sequences of the full length D2 
receptor and its longest domain, intracellular loop3 (D2-IL3), from the cDNA reversely 
transcribed from the rat hippocampal tissue. These samples (preparation as Section 2.2.3.3) 
were exposed to 30 cycles of PCR amplification with a denaturation temperature of 94℃ for 
40 seconds, an annealing temperature of 56℃ for 40 seconds and an extension temperature of 
72℃ for 90 seconds, using Vent DNA polymerase. 
    As mentioned previously, there were two different PCR products of the full length D2 
receptor. One PCR product flanked by “HindIII” & “EcoRI” (no “TGA”) was first cloned into 
pGEM-T Easy vector after the base “A” (adenosine) was added to the ends (3´) of this DNA 
fragment by holding the purified PCR product with 1 mM dATP, 1× PCR buffer and Taq DNA 
polymerase at 72℃ for 2 hours. This fragment was then subcloned into pcDNATM3.1 vectors 
after digested with “HindIII” & “EcoRI” from the pGEM-T Easy vector.  
The five fragments of D2-IL3 (D2-IL3Ⅰ/Ⅱ/Ⅲ/Ⅳ/Ⅴ) were obtained by PCR from the 
recombinant plasmid of D2-IL3 as the template DNA, using pfu DNA polymerase. The 
annealing temperature for 25 cycles of these PCR amplifications was 60℃ holding for 30 
seconds, followed by a 40 seconds extension. The second fragment of D2-IL3 (D2-IL3Ⅱ) is 
the additional 29 amino acids in the intracellular loop3 of the long form D2 receptor. 
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Figure 3.3: PCR products of the full length long form D2 receptor (1332 bp) and its 
intracellular loop3 (D2-IL3, 492 bp), electrophoresed on a 1% agarose gel and 
visualized with EtBr.  
 
 
 
 
Figure 3.4: PCR products of D2-IL3(Ⅰ) (93 bp), D2-IL3(Ⅱ) (87 bp), D2-IL3(Ⅲ) 
(105 bp), D2-IL3(Ⅳ) (105 bp) and D2-IL3(Ⅴ) (102 bp), electrophoresed on a 
1% agarose gel and visualized with EtBr.  
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3.2 Chromatograms Showing the Sequences of CB1 Receptor and D2 
Receptor Fragments 
    Each DNA fragment applied in this study was sequenced to confirm the correct 
sequence after it was cloned into an appropriate vector.     
  
3.2.1 Chromatograms Showing the Sequences of CB1 Receptor Fragments 
In total, ten DNA fragments of the CB1 receptor were sequenced in pGEX-2T or 
pcDNATM3.1/myc-His(B) vector after their cloning.  
One fragment of the full length CB1 receptor (no “TGA”) was directly cloned into the 
pcDNATM3.1/myc-His(B) vector and then forwardly sequenced with “T7 Promoter 
Sequencing Primer” (Figure 3.5) and reversely sequenced with “BGH Reverse Sequencing 
Primer” (Figure 3.6). Two bases were different with the DNA sequence found in Genbank, 
one at “902 bp (A instead of G)” and another at “1067 bp (T instead of C)”. These 
“substitutions” did not change the translated proteins. Another fragment of the full length 
CB1 receptor (including “TGA”) was sequenced in the pGEX-2T vector with forward 
“5´pGEX Sequencing Primer” and reverse “3´pGEX Sequencing Primer” to ensure its 
correct DNA sequence (data not shown). 
The other eight fragments of four extracellular and four intracellular domains of the 
CB1 receptor were cloned into the pGEX-2T vector and then forwardly sequenced with 
“5´pGEX Sequencing Primer”. Their sequencing data were illustrated below: CB1-NT 
(Figure 3.7), CB1-EL1 (Figure 3.8), CB1-EL2 (Figure 3.9), CB1-EL3 (Figure 3.10), 
CB1-IL1 (Figure 3.11), CB1-IL2 (Figure 3.12), CB1-IL3 (Figure 3.13), and CB1-CT 
(Figure 3.14).  
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Figure 3.5: Chromatogram of coding sequence (153~928 bp) of the CB1 receptor with the 
restriction site BamHI (underlined) in pcDNATM3.1/myc-His(B) vector, sequenced 
with the “T7 Promoter Sequencing Primer”. One base was different from the 
sequence found in Genbank at “902 bp (A instead of G)” marked by box, but it did 
not change the translated protein.  
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Figure 3.6: Chromatogram of coding sequence (1571~928 bp) of the CB1 receptor with the 
restriction site EcoRI (underlined) in pcDNATM3.1/myc-His(B) vector, sequenced 
with the “BGH Reverse Sequencing Primer”. One base was different from the 
sequence found in Genbank at “1067 bp (T instead of C)” marked by box, but it did 
not change the translated protein. 
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Figure 3.7: Chromatogram of the coding sequence (153~503 bp) of “CB1-NT” in 
pGEX-2T vector, sequenced with the “5´pGEX Sequencing Primer”. 
 
 
 
 85
  
 
 
Figure 3.8: Chromatogram of the coding sequence (681~716 bp) of “CB1-EL1” in 
pGEX-2T vector, sequenced with the “5´pGEX Sequencing Primer”.  
 
 
 
 
 
 
Figure 3.9: Chromatogram of the coding sequence (921~974 bp) of “CB1-EL2” in 
pGEX-2T vector, sequenced with the “5´pGEX Sequencing Primer”. 
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Figure 3.10: Chromatogram of the coding sequence (1251~1286 bp) of “CB1-EL3” in 
pGEX-2T, sequenced with the “5´pGEX Sequencing Primer”. 
 
 
 
 
 
 
Figure 3.11: Chromatogram of the coding sequence (582~617 bp) of “CB1-IL1” in 
pGEX-2T vector, sequenced with the “5´pGEX Sequencing Primer”. 
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Figure 3.12: Chromatogram of the coding sequence (792~851 bp) of “CB1-IL2” in 
pGEX-2T vector, sequenced with the “5´pGEX Sequencing Primer”. 
 
 
 
 
 
Figure 3.13: Chromatogram of the coding sequence (1053~1187 bp) of “CB1-IL3” in 
pGEX-2T vector, sequenced with the “5´pGEX Sequencing Primer”. 
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Figure 3.14: Chromatogram of the coding sequences (1353~1571 bp) of “CB1-CT” in 
pGEX-2T vector, sequenced with the “5´pGEX Sequencing Primer”. 
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3.2.2 Chromatograms Showing the Sequences of D2 Receptor Fragments  
    In total, fourteen DNA fragments of the D2 receptor were cloned into pGEM-T Easy, 
pET-28a(+) or pGEX-2T vectors and then sequenced.  
One fragment of the full length D2 receptor, flanked by “HindIII” & “EcoRI” (no 
“TGA”) for subcloning into pcDNATM3.1 vectors, was cloned into pGEM-T Easy vector, 
forwardly sequenced with “pUC/M13 Forward Sequencing Primer” (Figure 3.15) and 
reversely sequenced with “pUC/M13 Reverse Sequencing Primer” (Figure 3.16). One base 
was different from the sequence found in Genbank at “1210 bp (C instead of T)”, but this 
“substitution” did not change the translated protein. Another fragment of the full length D2 
receptor, incorporated with “EcoRI” & “XhoI” (including “TGA”), was directly cloned into 
the pET-28a(+) vector and then forwardly and reversely sequenced with “T7 Promoter 
Sequencing Primer” and “T7 Terminator Sequencing Primer”, respectively. The sequencing 
result was the same as above: one base was different from the sequence found in Genbank 
at “1210 bp (C instead of T)” (data not shown). 
The three short intracellular domains of the D2 receptor, i.e. D2-IL1 (Figure 3.17), 
D2-IL2 (Figure 3.18) and D2-CT (Figure 3.19), were sequenced in the pGEX-2T vector 
with forward “5´pGEX Sequencing Primer”. The PCR product of the intracellular loop3 
(D2-IL3), the longest domain of the D2 receptor, was forwardly sequenced with “T7 
Promoter Sequencing Primer” after it was cloned into the pET-28a(+) vector (Figure 3.20). 
Similar to the sequencing result of the full length D2 receptor, one base different from the 
sequence found in Genbank was also found at “1210 bp (C instead of T)”. The five 
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fragments of D2-IL3 (D2-IL3Ⅰ/Ⅱ/Ⅲ/Ⅳ/Ⅴ, Figure 3.21~25), produced by PCR using 
“D2-IL3 in pET-28a(+)” as template DNA, were cloned into the pGEX-2T vector and then 
sequenced with forward “5´pGEX Sequencing Primer”. The base different from the 
sequence found in Genbank at “1210 bp (C instead of T)” was identified in the third 
fragment (D2-IL3 Ⅲ). In addition, three motifs of the fourth fragment (D2-IL3 Ⅳ1/2/3), 
obtained by annealing with the synthetic DNA oligos, were also cloned into the pGEX-2T 
vector for forward sequencing (Figure 2.26~28).     
In all the illustrated sequencing data, the stop codon “TGA” and the bases different 
from the sequences found in Genbank were boxed, while the restriction sites incorporated 
at two ends of each DNA fragment were underlined.  
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Figure 3.15: Chromatogram of the coding sequence (347~1078) of the long form of the D2 
receptor with the restriction site HindIII (underlined) in pGEM-T Easy vector, 
sequenced with the “pUC/M13 Sequencing Primer”. 
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Figure 3.16: Chromatogram of the coding sequence (1678~1078) of the long form D2 
receptor with the restriction site EcoRI (underlined) in pGEM-T Easy vector, 
sequenced with “pUC/M13 Reverse Sequencing Primer”. One base was different 
from the sequence found in Genbank at “1210 bp (C instead of T)”, but it did not 
change the translated protein. 
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Figure 3.17: Chromatogram of the coding sequence (524~556 bp) of “D2-IL1” in 
pGEX-2T vector, sequenced with the “5´pGEX Sequencing Primer”. 
 
 
 
 
 
 
 
Figure 3.18: Chromatogram of the coding sequence (737~799 bp) of “D2-IL2” in 
pGEX-2T vector, sequenced with the “5´pGEX Sequencing Primer”. 
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Figure 3.19: Chromatogram of the coding sequence (1637~1678 bp) of “D2-CT” in 
pGEX-2T vector, sequenced with the “5´pGEX Sequencing Primer”. 
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Figure 3.20: Chromatogram of the coding sequence (977~1468 bp) of “D2-IL3 (L)” in 
pET-28a(+) vector, sequenced with the “T7 Promoter Sequencing Primer”. One 
base was different from the sequence found in Genbank at “1210 bp (C instead of 
T)”, but it did not change the translated protein. 
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Figure 3.21: Chromatogram of the coding sequence (977~1069 bp) of “D2-IL3 (Ⅰ)” in 
pGEX-2T vector, sequenced with the “5´pGEX Sequencing Primer”. 
 
 
 
 
 
 
Figure 3.22: Chromatogram of the coding sequence (1070~1156 bp) of “D2-IL3 (Ⅱ)” in 
pGEX-2T vector, sequenced with the “5´pGEX Sequencing Primer”. 
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Figure 3.23: Chromatogram of the coding sequence (1157~1261 bp) of “D2-IL3 (Ⅲ)” in 
pGEX-2T vector, sequenced with the “5´pGEX Sequencing Primer”. One base was 
different from the sequence found in Genbank at “1210 bp (C instead of T)”, but it 
did not change the translated protein. 
 
 
 
  
 
 
 
Figure 3.24: Chromatogram of the coding sequence (1367~1468 bp) of “D2-IL3 (Ⅴ)” in 
pGEX-2T vector, sequenced with the “5´pGEX Sequencing Primer”. 
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Figure 3.25: Chromatogram of the coding sequence (1262~1366 bp) of “D2-IL3 (Ⅳ)” in 
pGEX-2T vector, sequenced with the “5´pGEX Sequencing Primer”. 
 
 
 
 
 
 
Figure 3.26: Chromatogram of the coding sequence (1262~1297 bp) of “D2-IL3 (Ⅳ1)” in 
pGEX-2T vector, sequenced with the “5´pGEX Sequencing Primer”. 
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Figure 3.27: Chromatogram of the coding sequence (1298~1333 bp) of “D2-IL3 (Ⅳ2)” in 
pGEX-2T vector, sequenced with the “5´pGEX Sequencing Primer”. 
 
 
 
 
 
 
 
Figure 3.28: Chromatogram of the coding sequence (1334~1366 bp) of “D2-IL3 (Ⅳ3)” in 
pGEX-2T vector, sequenced with the “5´pGEX Sequencing Primer”. 
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3.3 Over-Expression and Purification of Fusion Proteins in E. coli Cells 
 
    To over-express fusion proteins in E.coli cells, the recombinant plasmids were 
transformed into appropriate competent cells and then induced with 1.0 mM IPTG, 
followed by visualization in SDS-PAGE gel using Coomassie Blue stain. To over-express 
GST fusion proteins, the DNA fragments were ligated into pGEX-2T or pGEX-6P-1 vector 
and transformed into BL21 competent cells. However, to over-express 6His fusion proteins, 
the pET-28a(+) vector was used to clone or subclone the DNA fragments and DE3 
competent cells were employed for the transformation of the recombinant plasmids.  
    The full length CB1 receptor was first cloned into pGEX-2T vector, and then 
subcloned into pGEX-6P-1 vector (since it could not be expressed in pGEX-2T vector) and 
into pET-28a(+) vector for obtaining 6His fusion protein of the CB1 receptor. The full 
length D2 receptor was respectively cloned into pET-28a(+) and pGEX-6P-1 vectors to get 
its 6His and GST fusion proteins. However, the GST or 6His fusion proteins of the full 
length CB1 and D2 receptors could not be induced to over-express in E.coli cells. 
    After over-expression, GST and 6His fusion proteins were purified from the E.coli 
cells, respectively, using Glutathione Sepharose 4B beads and Ni-NTA His•Bind resins (see 
Section 2.2.11).  
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3.3.1 Fusion Proteins of CB1 Receptor Fragments 
    The GST fusion proteins of four intracellular domains (GST-CB1-CT/IL1/IL2/IL3) 
and four extracellular domains (GST-CB1-NT/EL1/EL2/EL3) of the CB1 receptor were 
successfully over-expressed in BL21 competent cells and purified from these cells (Figure 
3.29). The expected molecular weights of these GST fusion proteins are listed below: 
27KDa for GST-CB1-IL1/EL1/EL3, 28KDa for GST-CB1-EL2/IL2, 31KDa for 
GST-CB1-IL3, 34KDa for GST-CB1-CT and 39KDa for GST-CB1-NT.   
In another experiment, the DNA fragment of CB1-CT was subcloned into the 
pET-28a(+) vector to over-express its 6His fusion protein in DE3 competent cells, followed 
by purification using Ni-NTA His•Bind resins. The molecular weight of this 6His fusion 
protein of CB1-CT (6His-CB1-CT) was 15KDa (Figure 3.30), which could be visualized in 
the 14% SDS-PAGE gel through protein staining. 
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Figure 3.29: Over-expressed (A) and purified (B) GST fusion proteins of four intracellular 
domains (GST-CB1-CT/IL1/IL2/IL3) and four extracellular domains 
(GST-CB1-NT/EL1/EL2/EL3) of the CB1 receptor with their expected molecular 
weights listed between A and B. GST protein as a control. 
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    Figure 3.30: Over-expressed and purified 6His fusion protein of CB1-CT.  
       (6His-CB1-CT: 15KDa) 
      M: protein marker 
      1: over-expressed 6His-CB1-CT 
      2: purified 6His-CB1-CT 
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3.3.2 Fusion Proteins of D2 Receptor Fragments 
The 6His fusion proteins of D2-L3 (6His-D2-IL3: 26KDa) were successfully 
over-expressed by inducing with IPTG in DE3 competent cells, and then purified by 
Ni-NTA His•Bind resins (Figure 3.31). In addition, this DNA fragment of D2-IL3 was also 
subcloned into pGEX-2T for over-expression and purification of the GST fusion protein of 
D2-IL3 (GST-D2-IL3: 44KDa) in BL21 cells (Figure 3.32). Three other intracellular 
domains of the D2 receptor were also inserted into pGEX-2T to over-express their GST 
fusion proteins (GST-D2-IL1: 27KDa, GST-D2-IL2: 28.5KDa and GST-D2-CT: 27.5KDa), 
which were then purified with Glutathione Sepharose 4B-beads (Figure 3.33). 
GST fusion proteins of five fragments of D2-IL3 (GST-D2-IL3Ⅰ/Ⅱ: 29KDa and 
GST-D2-IL3Ⅲ/Ⅳ/Ⅴ: 30KDa, Figure 3.34) and three motifs of D2-IL3(Ⅳ) (GST-D2-IL3 
Ⅳ1/2/3: 27KDa, Figure 3.35) were over-expressed after cloning into pGEX-2T vector and 
transforming into BL21 competent cells.     
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Figure 3.31: Purified 6His fusion protein of D2-IL3. (6His-D2-IL3: 26KDa)  
       M: protein marker 
       P: purified 6His-D2-IL3 
 
 
 
 
 
Figure 3.32: Over-expressed and purified GST fusion protein of D2-IL3. 
           (GST-D2-IL3: 44KDa) 
       1: control (non-induced sample) 
                2: over-expressed GST-D2-IL3 
                3: purified GST-D2-IL3 
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Figure 3.33: Purified GST fusion proteins of four intracellular domains of the D2 
receptor (GST-D2-IL1/IL2/IL3/CT) with their expected molecular 
weights listed at the bottom.  
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Figure 3.34: Over-expressed GST fusion proteins of the five fragments of D2-IL3 
(GST-D2-IL3Ⅰ/Ⅱ/Ⅲ/Ⅳ/Ⅴ) with their molecular weights at the bottom. 
 
 
 
 
 
 
Figure 3.35: Over-expressed GST fusion proteins of the three motifs of D2-IL3(Ⅳ), 
GST-D2-IL3(Ⅳ1/2/3): 27KDa. 
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3.4 Expression of Tagged Proteins Containing the full length CB1 and D2 
Receptors in Mammalian Cells 
   Since the full length CB1 and D2 receptors could not be over-expressed in E.coli cells, 
an attempt was made to express them and their recombinant proteins with  
“-myc” or “-FLAG” in mammalian cells using the recombinant plasmids, i.e. 
“CB1 in  pcDNA™3.1 /myc -His (B)” ,  “CB1 in  pcDNA™3.1/FLAG(B)” , 
“CB1(TGA) in pcDNA™3.1/myc-His(B)”, “D2 in pcDNA™3.1/myc-His(B)”, and  
“D2 in pcDNA™3.1/FLAG(B)”.  
 
3.4.1 Transfection Efficiency in HEK293 and PC12 Cells 
    For expression of proteins in mammalian cells, the first important step is to perform 
the efficient transient transfection of the recombinant plasmids.  
Two mammalian cell lines (i.e. HEK293 and PC12 cells) were tried for transient 
transfection with LipofectamineTM 2000 reagent. To identify the transfection efficiency, the 
vector containing GFP was used. Figure 3.36, taken under fluorescence correlation 
microscopy 24 hours after transfection, showed that HEK293 cells had a much higher 
transfection efficiency than PC12 cells. Therefore, HEK293 cells were chosen for 
transfection to express proteins of the full length CB1 and D2 receptors as well as their 
tagged recombinant proteins in this study.  
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To further prove efficient transfection, RT-PCR was applied to amplify the DNA 
sequences of the full length CB1 (Figure 3.37, Lane 1´, 2´and 3´) or D2 (Figure 3.37, 
Lane 1, 2 and 3) receptors, using the cDNAs reversely transcribed from the non-transfected 
HEK293 cells (Figure 3.37, Lane 1 and 1´), HEK293 cells transfected with 
pcDNA™3.1/myc-His(B) empty vectors (Figure 3.37, Lane 2 and 2´) or recombinant 
vectors of “CB1 in pcDNA™3.1/myc-His(B)” (Figure 3.37, Lane 3´) and “D2 in 
pcDNA™3.1/myc-His(B)” (Figure 3.37, Lane 3). The DNA fragments of the full length 
CB1 or D2 receptor could be only amplified by RT-PCR using the cDNA from the HEK293 
cells transfected with their recombinant vectors (Figure 3.37, Lane 3´ and 3). These results 
clearly demonstrate an efficient transfection with LipofectamineTM 2000 reagent. 
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Figure 3.36: GFP identification of efficient transfection. The vector containing GFP was 
transfected into HEK293 and PC12 cells.  
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Figure 3.37: RT-PCR identification of efficient transfection. RT-PCR was applied to 
amplify the DNA sequences of the full length CB1 or D2 receptor, using the cDNAs 
reversely transcribed from the non-transfected HEK293 cells, the HEK293 cells 
transfected with “pcDNA™3.1/myc-His(B)” empty vectors or recombinant vectors 
of “CB1 in pcDNA™3.1/myc-His(B)” and “D2 in pcDNA™3.1/myc-His(B)”. 
       M: 1Kb DNA ladder 
     1 & 1´: cDNA from non-transfected HEK293 cells 
     2 & 2´: cDNA from HEK293 cells transfected with “pcDNA™3.1/myc-His(B)”  
     3´: cDNA from HEK293 cells transfected with “CB1 in pcDNA™3.1/myc-His(B)” 
     3: cDNA from HEK293 cells transfected with “D2 in pcDNA™3.1/myc-His(B)” 
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3.4.2 Expressed Proteins Were Difficult to Detect by Western Blot  
Western blot was used to determine whether the proteins of the full length CB1 and D2 
receptors were expressed after the transfection of relevant expression plasmids into HEK293 
cells in this study (negative or similar results not shown). 
As described above, five recombinant plasmids of the full length CB1 and D2 receptors 
were transfected into HEK293 cells for expression. For each recombinant plasmid, a dose of 
either 2 μg or 4 μg of transfected DNA for each well of a 6-well plate and different growing 
times of 24/36/48/72 hours after transfection were carried out for their expression. Then, 
five primary antibodies, i.e. anti-CB1 (44-310, Biosource, Camarillo, CA), anti-D2 
(AB1558, Chemicon, Temecula, CA), anti-His (27E8, Cell Signaling, Danvers, MA), 
anti-myc (c2905, Santa Cruz Biotechnology, Santa Cruz, CA) and anti-FLAG (#2368, Cell 
Signaling, Danvers, MA) antibodies, were employed to detect expressed proteins. 
For the HEK293 cells transfected with “CB1(TGA) in pcDNA™3.1/myc-His(B)” or 
“CB1/D2 in pcDNA™3.1/FLAG(B)”, no specific bands could be identified in the western 
blot experiments using “anti-CB1” (1:500) or “anti-FLAG” (1:200) primary antibodies 
(data not shown). The western blot experiments of the “D2 in pcDNA™3.1/myc-His(B)” 
transfected HEK293 cells with different growing time after transfection, detected with 
“anti-D2” (1:500), “anti-His” (1:1000) or “anti-myc” (1:500) primary antibodies, showed 
some bands (Figure 3.38). However, the expected specific bands (i.e. around 53KDa) of the 
expressed proteins detected with these three primary antibodies could not be found. The 
over-expressed fusion protein of “CB1-myc” (around 56KDa) could occasionally be 
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detected with “anti-CB1” (1:500) primary antibody in western blot after the recombinant 
plasmids of “CB1 in pcDNA™3.1/myc-His(B)” were transfected into HEK293 cells (see 
Figure 3.39, Lane “CB1-myc”).  
 
 
 
 
 
 
 
Figure 3.38: Western blot experiments of HEK293 lysates transfected with “D2 in 
pcDNA™3.1/myc-His(B)” and allowed to grow for 24, 36, 48 or 72 hours after 
transfection, were detected with “anti-D2”, “anti-His” or “anti-myc” primary 
antibodies. The expected 53KDa protein band could not be detected. 
Non-transfected HEK293 cells were used as “control”. 
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Figure 3.39: Western blot experiments of HEK293 lysates transfected, with either 2 μg or 4 
μg of “CB1 in pcDNA™3.1/myc-His(B)” and allowed to grow for 24, 48 or 72 
hours after transfection, were probed with “anti-CB1” primary antibody. The 
over-expressed fusion protein of “CB1-myc” (around 56KDa) could occasionally be 
identified (Lane “CB1-myc”). The HEK293 cells non-transfected or transfected 
with empty vectors of “pcDNA™3.1/myc-His” were used as controls. 
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3.4.3 Troubleshooting for the Low Expression Level of Tagged Proteins Containing 
Full Length CB1 and D2 Receptors 
    Since transient expression of the tagged fusion proteins of the full length CB1 and D2 
receptors was not successful in transfected HEK293 cells, troubleshooting has been 
performed to try to solve the problems.  
To make sure if excessive proteins were loaded into SDS-PAGE gel, different amounts 
of proteins were chosen for analysis. Another possibility is that the expressed proteins only 
existed in the floating transfected cells, and therefore the floating cells were collected alone 
after transfection and then analyzed by western blot. In addition, nine nucleotides 
(incorporating a Kozak consensus sequence to enhance gene expression) were added before 
the CB1 and D2 receptor open reading frames after these two DNA fragments were 
amplified by RT-PCR, cloned and subcloned into pcDNA™3.1/myc-His(B) vectors and 
transfected with their sequenced recombinant vectors into HEK293 cells.  
However, these 3 modified experiments still did not show positive results, namely, 
both CB1 and D2 receptors were not found to be over-expressed (Figure 3.40). Because 
strong signal exists in the stacking gel shown in Figure 3.40 (Lane “20 μl”), it is possible 
that the expressed fusion protein aggregated with other proteins and was unable to enter the 
resolving gel. 
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Figure 3.40: Western Blot for troubleshooting of transient expression of tagged 
recombinant protein (“CB1-myc”) in HEK293 cells using “anti-myc” primary 
antibody.  
CB1-myc (adhering cells): different amounts (1/5/10/20 μl) of protein from 
adhering HEK293 cells transfected with “CB1 in pcDNA™3.1/myc-His(B)” 
were loaded for analysis. 
floating cells: proteins from floating HEK293 cells transfected with “CB1 in 
pcDNA™3.1/myc-His(B)” were prepared for analysis. 
 “CB1+9”-myc: nine bases were added before the CB1 receptor gene coding   
    sequence. 
pcDNA3.1: HEK 293 cells transfected with “pcDNA™3.1/myc-His”. 
HEK293: non-transfected HEK293 cells. 
marker: protein ladder. 
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3.5 Pull-Down Assays 
In this study, pull-down assay was employed to explore the possible protein-protein 
interaction between the CB1 and D2 receptors. The “GST” or “6His” tagged fusion 
proteins were used as bait protein in all the pull-down assays, which were classified as “in 
vitro pull-down assay” and “semi-in vivo pull-down assay”.  
 
3.5.1 In Vitro Pull-Down Assays 
    For “in vitro pull-down assay”, the bacterial cell lysate containing the over-expressed 
6His or GST fusion proteins was applied as the lysate sample. “In vitro GST pull-down 
assay” consists of two steps. First, the bead-bound GST tagged fusion proteins would act as 
the bait protein to pull-down prey proteins from the bacteria cell lysate containing the 
over-expressed 6His recombinant proteins. Then, the “anti-His” primary antibody was used 
in western blot to detect the prey proteins in pull-down complexes. For “in vitro 6His 
pull-down assay”, the resin-bound 6His tagged fusion proteins were employed as the bait 
protein to pull-down prey proteins from the bacteria cell lysate containing the 
over-expressed GST recombinant proteins, and then the prey proteins in pull-down 
complexes were detected by the “anti-GST” (26H1, Cell Signaling, Danvers, MA) primary 
antibody in western blot.   
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3.5.1.1 Pull-Down Between “CB1-CT” and “D2-IL3”  
    It has been shown that long intracellular fragments of GPCRs are possibly more likely 
to form their protein-protein interactions than short fragments (Lee et al., 2002; Liu et al., 
2000; Milligan and White, 2001; Zou et al., 2005). Therefore, in vitro GST pull-down assay 
was applied to study the interaction between CB1 C-terminal (CB1-CT) or CB1 
intracellular loop3 (CB1-IL3) and D2 intracellular loop3 (D2-IL3), which are the longer 
intracellular domains of the CB1 and D2 receptors.  
The beads-bound GST tagged fusion proteins of CB1-CT (GST-CB1-CT) or CB1-IL3 
(GST-CB1-IL3) were used as the bait proteins to pull-down the 6His recombinant protein 
of D2-IL3 (6His-D2-IL3) from the bacterial cell lysate containing the over-expressed 
6His-D2-IL3 (Figure 3.41 A). The beads-bound GST protein was used as a negative control 
to pull-down 6His-D2-IL3 (Figure 3.41 A, Lane “GST”). Another negative control was the 
fusion protein of GST-CB1-CT without incubation with the bacterial cell lysate (Figure 
3.41 A, Lane “control”). The result of western blot, detected with “anti-His” (1:1000) 
primary antibody, suggests that GST-CB1-CT could pull-down 6His-D2-IL3 from the 
bacterial cell lysate. 
Next, the beads-bound GST tagged fusion proteins of D2-IL3 (GST-D2-IL3) were 
applied as the bait protein to pull-down the 6His recombinant protein of CB1-CT 
(6His-CB1-CT) from the bacterial cell lysate containing the over-expressed 6His-CB1-CT 
(Figure 3.41 B). The fusion protein of GST-D2-IL3 without incubation with the bacterial 
cell lysate and the beads-bound GST protein to pull-down 6His-CB1-CT were employed as 
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negative controls (Figure 3.41 B, Lane “control” and “GST”). The detection with 
“anti-His” (1:1000) primary antibody in western blot indicates that GST-D2-IL3 could 
pull-down 6His-CB1-CT from the bacterial cell lysate. 
All the above results from in vitro GST pull-down assays suggest that D2 intracellular 
loop3 (D2-IL3) and CB1 C-terminal (CB1-CT) could directly couple to each other.  
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Figure 3.41: “D2-IL3” and “CB1-CT” could directly couple to each other.  
A: In vitro GST pull-down assays were performed using “GST-CB1-CT” and 
“GST-CB1-IL3”. Resolved pull-down complexes were examined for the 
presence of “6His-D2-IL3”. 
lysate: the bacterial cell lysate containing over-expressed “6His-D2-IL3”. 
         CB1-CT: “GST-CB1-CT” was used as bait for pull-down. 
         CB1-IL3: “GST-CB1-IL3” was used as bait for pull-down. 
         control: beads-bound “GST-CB1-CT” without incubation with the lysate. 
         GST: beads-bound GST protein was used as bait for pull-down. 
B: In vitro GST pull-down assay was performed using “GST-D2-IL3”. Resolved 
pull-down complex was examined for the presence of “6His-CB1-CT”. 
lysate: the bacterial cell lysate containing over-expressed “6His-CB1-CT”. 
         D2-IL3: “GST-D2-IL3” was used as bait for pull-down. 
         control: beads-bound “GST-D2-IL3” without incubation with the lysate. 
         GST: beads-bound GST protein was used as bait for pull-down. 
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3.5.1.2 Identification of Specific Motifs “D2-IL3 (Ⅳ1/3)” 
    To determine if C-terminal (CB1-CT) is the only intracellular domain of the CB1 
receptor that can interact with D2-IL3, in vitro 6His pull-down assays were carried out. In 
this experiment (Figure 3.42), the resins-bound 6His tagged fusion protein of D2-IL3 
(6His-D2-IL3) was used as bait protein to pull-down GST recombinant proteins of all 
intracellular domains of the CB1 receptor (GST-CB1-IL1/IL2/IL3/CT) from the bacterial 
cell lysates containing these over-expressed GST recombinant proteins; the over-expressed 
GST protein was employed as a negative control. The “last wash” of each pull-down 
complex was prepared for western blot to exclude the possibility of contamination of the 
pull-down complexes by excessive concentrations of bacterial cell lysates. The result from 
this experiment indicates that D2-IL3 could only pull-down CB1-CT, but not other CB1 
intracellular domains. 
The same method was employed to prove that intracellular loop3 (D2-IL3) is the only 
intracellular domain of the D2 receptor that can couple with CB1-CT. The resins-bound 
6His tagged fusion protein of CB1-CT (6His-CB1-CT) was applied as bait protein to 
pull-down GST recombinant proteins of all intracellular domains of the D2 receptor 
(GST-D2-IL1/IL2/IL3/CT) from the bacterial cell lysates containing these over-expressed 
GST recombinant proteins; the over-expressed GST protein was employed as a negative 
control (Figure 3.43). The “last wash” of each pull-down complex was also prepared to 
exclude the possibility of contamination of pull-down complexes by excessive 
concentrations of bacterial cell lysates. The results of western blot, detected with 
“anti-GST” (1:1000) primary antibody, suggest that CB1-CT could only pull-down D2-IL3, 
but not other D2 intracellular domains. 
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Figure 3.42: “D2-IL3” could only pull-down “CB1-CT”, but not other CB1 intracellular 
domains. In vitro 6His pull-down assays were performed using “6His-D2-IL3”. 
Resolved pull-down complexes were respectively examined for the presence of 
“GST-CB1-IL1/IL2/IL3/CT”.  
      lysate: bacterial cell lysates containing over-expressed proteins of “GST” or  
           “GST-CB1-IL1/IL2/IL3/CT”. 
      last wash: wash buffer of the last wash of each pull-down complex. 
      GST: Bacterial cell lysate containing over-expressed “GST” was used as a 
            lysate sample for pull-down. 
      CB1-IL1: Bacterial cell lysate containing over-expressed “GST-CB1-IL1”was 
            used as a lysate sample for pull-down. 
      CB1-IL2: Bacterial cell lysate containing over-expressed “GST-CB1-IL2”was used 
as a lysate sample for pull-down. 
      CB1-CT: Bacterial cell lysate containing over-expressed “GST-CB1-CT” was used 
as a lysate sample for pull-down. 
      CB1-IL3: Bacterial cell lysate containing over-expressed “GST-CB1-IL3” was   
used as a lysate sample for pull-down. 
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Figure 3.43: “CB1-CT” could only pull-down “D2-IL3”, but not other D2 intracellular 
domains. In vitro 6His pull-down assays were performed using “6His-CB-CT”. 
Resolved pull-down complexes were respectively examined for the presence of 
“GST-D2-IL1/IL2/IL3/CT”.  
      lysate: bacterial cell lysates containing over-expressed proteins of “GST” or 
“GST-D2-IL1/IL2/IL3/CT”. 
      last wash: wash buffer of the last wash of each pull-down complex. 
      D2-IL1: Bacterial cell lysate containing over-expressed “GST-D2-IL1” was used as 
a lysate sample for pull-down. 
      D2-IL2: Bacterial cell lysate containing over-expressed “GST-D2-IL2” was used as 
a lysate sample for pull-down. 
      GST: Bacterial cell lysate containing over-expressed “GST” was used as a lysate 
sample for pull-down. 
           D2-CT: Bacterial cell lysate containing over-expressed “GST-D2-CT” was used as a 
lysate sample for pull-down. 
      D2-IL3: Bacterial cell lysate containing over-expressed “GST-D2-IL3” was used as 
a lysate sample for pull-down. 
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Next, the intracellular loop3 of the D2 receptor, the longest domain of the D2 receptor, 
was divided into five fragments (D2-IL3Ⅰ/Ⅱ/Ⅲ/Ⅳ/Ⅴ). To identify which fragment is 
responsible for the coupling between “CB1-CT” and “D2-IL3”, the 6His tagged fusion 
protein of “CB1-CT” (6His-CB1-CT) was used to pull down GST recombinant proteins of 
these five fragments (GST-D2-IL3Ⅰ/Ⅱ/Ⅲ/Ⅳ/Ⅴ) from their bacterial cell lysates (Figure 
3.44). The results suggest that the fourth fragment of “D2-IL3” (D2-IL3 Ⅳ) is the main 
fragment responsible for in vitro coupling between the CB1 and D2 receptors. 
To further narrow down the motif responsible for the coupling between “CB1-CT” and 
“D2-IL3”, the fourth fragment of “D2-IL3” (D2-IL3 Ⅳ), which includes 35 amino acids, 
was partitioned into three motifs: D2-IL3(Ⅳ1) (12aa), D2-IL3(Ⅳ2) (12aa) and D2-IL3(Ⅳ3) 
(11aa). The 6His tagged fusion protein of “CB1-CT” (6His-CB1-CT) was used again to 
pull down the GST recombinant proteins of these three motifs (GST-D2-IL3 Ⅳ1/2/3) from 
their bacterial cell lysates (Figure 3.45). Results indicate that the first and third motifs in 
the fourth fragment of D2 intracellular loop3 (D2-IL3 Ⅳ1 and Ⅳ3) are likely the specific 
motifs responsible for the in vitro coupling between the CB1 and D2 receptors. 
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Figure 3.44: The fourth fragment of “D2-IL3” is likely the major fragment responsible for 
the coupling of “CB1-CT” with “D2-IL3”. In vitro 6His pull-down assays were 
performed using “6His-CB-CT”. Resolved complexes were respectively examined 
for the presence of “GST-D2-IL3(Ⅰ/Ⅱ/Ⅲ/Ⅳ/Ⅴ)”.  
      lysate: bacterial cell lysates containing over-expressed proteins of “GST” 
            or “GST-D2-IL3(Ⅰ/Ⅱ/Ⅲ/Ⅳ/Ⅴ)”. 
      last wash: wash buffer of the last wash of each pull-down complex. 
      GST: Bacterial cell lysate containing over-expressed “GST” was used as a 
lysate sample for pull-down. 
      D2-IL3(Ⅰ): Bacterial cell lysate containing over-expressed “GST- D2-IL3(Ⅰ)” 
was used as a lysate sample for pull-down. 
      D2-IL3(Ⅱ): Bacterial cell lysate containing over-expressed “GST- D2-IL3(Ⅱ)” 
  was used as a lysate sample for pull-down. 
      D2-IL3(Ⅲ): Bacterial cell lysate containing over-expressed “GST- D2-IL3(Ⅲ)”  
 was used as a lysate sample for pull-down. 
D2-IL3(Ⅳ): Bacterial cell lysate containing over-expressed “GST- D2-IL3(Ⅳ)”  
 was used as a lysate sample for pull-down. 
      D2-IL3(Ⅴ): Bacterial cell lysate containing over-expressed “GST- D2-IL3(Ⅴ)” 
  was used as a lysate sample for pull-down. 
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Figure 3.45: The first and third motifs in the fourth fragment of D2-IL3 (D2-IL3 Ⅳ1/3) 
are likely the specific motifs responsible for the coupling of “CB1-CT” with 
“D2-IL3”. In vitro 6His pull-down assays were performed using “6His-CB-CT”. 
Resolved complexes were respectively examined for the presence of 
“GST-D2-IL3(Ⅳ1/2/3)”. 
  lysate: bacterial cell lysates containing over-expressed proteins of 
“GST-D2-IL3(1/2/3)”. 
      last wash: wash buffer of the last wash of each pull-down complex. 
      D2-IL3(Ⅳ1): Bacterial cell lysate containing over-expressed “GST- D2-IL3(Ⅳ1)”  
   was used as a lysate sample for pull-down. 
  D2-IL3(Ⅳ2): Bacterial cell lysate containing over-expressed “GST- D2-IL3(Ⅳ2)” 
    was used as a lysate sample for pull-down 
      D2-IL3(Ⅳ3): Bacterial cell lysate containing over-expressed “GST- D2-IL3(Ⅳ3)” 
    was used as a lysate sample for pull-down. 
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3.5.2 Semi-In Vivo Pull-Down Assays 
For “semi-in vivo pull-down assay”, the rat striatum lysate was incubated with the 
purified GST tagged fusion proteins. To validate this experimental method, the GST tagged 
fusion protein of NDRG4 (GST-NDRG4) was used to successfully pull-down Erk proteins 
from the rat striatum lysate (Figure 3.46). 
GST tagged fusion proteins of all the extracellular and intracellular domains of the 
CB1 receptor (GST-CB1-IL1/IL2/IL3/CT/NT/EL1/EL2/EL3) were purified by Glutathione 
Sepharose beads and then used to pull-down D2 receptors from the normal rat striatum 
lysate (Figure 3.47). The fusion GST fusion proteins without incubation with the lysate 
(Figure 3.47, Lane “control”) and the beads-bound GST protein alone (Figure 3.47, Lane 
“GST”) were used as controls. The western blot experiments of these pull-down assays, 
which were detected with “anti-D2” (1:500) primary antibody, showed that no obvious 
specific band of the D2 receptor (50KDa) could be detected in most pull-down complexes 
(Figure 3.47 A and B), except that there was a weak band close to the lysate D2 band (Lane 
“CB1-IL3” in Figure 3.47B). To confirm whether this represents specific band, the 
pull-down assay was repeated with the beads-bound GST tagged fusion protein of CB1 
intracellular loop3 (GST-CB1-IL3) without incubation with the rat striatum lysate as a 
control. It was found that the weak band close to the lysate D2 band was a non-specific 
band (Figure 3.47 C).These results indicate that beads-bound GST tagged fusion proteins 
of CB1 fragments could not pull-down D2 receptors in in vivo situation, or that no 
protein-protein interaction occurs between CB1 and D2 receptors in in vivo condition.  
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Figure 3.46: A validation of experimental method of “semi-in vivo pull-down assay”.     
GST fusion proteins of NDRG4 could pull-down Erk proteins from the rat striatum 
lysate.  
            marker: protein ladder. 
        lysate: normal rat striatum lysate. 
  NDRG4: “GST-NDRG4” was used as bait for pull-down. 
  GST: “GST” was used as bait for pull-down. 
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Figure 3.47: Semi-in vivo pull-down assays were performed using GST fusion proteins of 
all the extracellular and intracellular domains of the CB1 receptor 
(GST-CB1-IL1/IL2/IL3/CT/NT/EL1/EL2/EL3). Resolved complexes were 
examined for the presence of the D2 receptor. Western blot did not detect the D2 
receptor in all the pull-down complexes.  
  marker: protein ladder. 
  lysate: normal rat striatum lysate (D2: 50KDa). 
      GST: “GST” was used as bait for pull-down. 
      control: beads-bound GST fusion proteins without incubation with lysate.  
  A: “GST-CB1- NT/EL1/EL2/EL3” proteins were used as bait for pull-down. 
  B: “GST-CB1-IL1/IL2/IL3/CT” were used as bait proteins for pull-down. 
  C: “GST-CB1-IL3” was used as bait for pull-down (repeat). 
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4  DISCUSSION 
 
4.1 Over-Expression of Full Length CB1 and D2 Receptors 
To determine the biological function of a protein, it is important to isolate and 
characterize the protein in vitro. Therefore, the protein of interest has to be over-expressed 
and then purified from a biological sample by “expression systems”, which are designed to 
control transcription of the cloned gene and translational efficiency and stability of the 
protein. These systems allow the production of large amounts of the protein relative to all 
other proteins in the cell. In present study, the tagged fusion proteins containing the full 
length CB1 and D2 receptors were tried for over-expression in E.coli bacteria and 
mammalian cell lines.   
However, no obvious expression of GST or 6His fusion proteins containing the full 
length CB1 and D2 receptors could be identified by protein staining in three E.coli strains, i.e. 
DH5α, BL21 and DE3. It is possible that the protein may be toxic to the cell when expressed 
at high levels. Alternatively, the over-expressed proteins may not be soluble when present at 
very high concentrations.  
Unstable transient expression of the tagged fusion proteins containing the full length 
CB1 and D2 receptors has been detected in HEK293 and PC12 cells efficiently transfected 
with both receptors, but no specific bands of the recombinant proteins of “D2-FLAG” and 
“CB1-FLAG” could be found in the western blot experiments. Specifically, the expected 
specific bands (i.e. around 53KDa) of the expressed proteins “D2-myc/His” could not be 
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consistently detected with “anti-D2”, “anti-His” or “anti-myc” primary antibodies. The 
over-expressed fusion protein “CB1-myc” (around 56KDa) could occasionally be identified 
with “anti-CB1” primary antibody in western blot. Further troubleshooting experiments 
were performed: (ⅰ) excessive proteins were loaded onto the SDS-PAGE gel; (ⅱ) lysates 
from adherent cells as well as from “floating” cells were examined; (ⅲ) an additional nine 
nucleotides were added before the coding sequences of CB1 and D2 receptors for their 
expression (this additional sequence might act as a Kozak sequence for enhancing gene 
expression). It is found that (ⅰ) a strong signal exists in the stacking gel; (ⅱ) the proteins 
were not detected in “floating” cells; and (ⅲ) the additional nine nucleotides had no effect. 
These results suggest that the expressed fusion protein may aggregate with other proteins to 
form a huge complex that it does not resolve on the SDS-PAGE. Another possibility for the 
failure of detection in Western blot is a potentially inefficient antibody.  
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4.2 Protein-Protein Interaction between CB1 and D2 Receptors     
    GPCRs, which constitute by far the largest family of cell surface proteins involved in 
signaling across biological membranes, modulate a wide range of physiological processes 
and are implicated in numerous diseases. It has been shown that cells co-transfected with 
two types of GPCRs and treated with agonist specific for one or the other receptor 
displayed ligand-binding profiles much different from cells expressing either receptor 
individually. These results indicate that the physical protein-protein interaction between 
two types of receptors, i.e. heterodimerization, is an important mechanism for the 
modulation of GPCR function. Indeed, the heterodimerization of GPCRs has gained much 
support over the past several years, for instance, the dimerization between dopamine D2 
and D3 receptors, κ and δ opioid receptors, somatostatin SSTR5 and dopamine D2(L) 
receptors, dopamine D1 and adenosine A1 receptors, α  adrenergic and m2 3 muscarinic 
receptors (Jordan and Devi, 1999; Park et al., 2004; Rocheville et al., 2000b; Scarselli et al., 
2001; Vazquez-Prado et al., 2002). 
    Both cannabinoid CB1 and dopamine D2 receptors are the most common GPCRs in 
the brain and are known to couple to the G protein Gαi/o. Various lines of evidence support 
the idea that direct protein-protein interaction occurs between CB1 and D2 receptors that 
regulates their functions. In order for different types of receptors to physically interact, 
they must exist within the same cells. It has been demonstrated that the CB1 and D2 
receptors are co-expressed within the same neurons in the striatum, olfactory tubercle, 
hippocampus and some cortical areas of adult mouse forebrain (Hermann et al., 2002). 
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Functional studies also indicate the existence of protein-protein interaction between CB1 
and D2 receptors in animals: when animals were treated with a CB1 agonist combined with 
either dopamine agonist or antagonist, the dopamine ligands dramatically affected 
cannabinoid-induced learning and memory impairment in rats, as well as motor function in 
mice (Gessa et al.，2000; Wager-Miller et al., 2002). Cell culture studies further support the 
existence of a CB1:D2 complex that can modulate the function of both receptors: the 
concurrent activation of D2 receptors and CB1 receptors promotes the coupling of CB1 
receptors to Gαs, instead of Gαi/o resulting in elevation in intracellular cAMP accumulation 
in primary striatal neuronal culture and HEK293 cells cotransfected with D2 and CB1 
receptors (Glass and Felder, 1997; Jarrahian et al., 2004). The direct evidence supporting 
the existence of direct protein-protein coupling between CB1 and D2 receptors comes from 
the observation of Kearn and his colleagues that co-IP experiments showed physically 
interaction of CB1 receptor with D2 receptors in HEK293 cells stably expressing both 
receptors (Kearn et al., 2005). The important question is which domain(s) and protein 
sequence(s) in the D2 and CB1 receptors are responsible for in vitro protein-protein 
interactions between both receptors.  
   Particular importance has been ascribed to the C-terminal (CT) and the third 
intracellular loop (IL3) of GPCRs in the formation of their di/oligomers (Milligan and 
White, 2001). It has been found that the D2 receptor can interact with actin-binding protein 
(ABP-280) via its third intracellular loop; this was originally identified in a yeast 
two-hybrid screen and confirmed by protein binding assays (Li et al., 2000). Agonist 
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stimulation of D2 receptors promotes the formation of the direct protein-protein interaction 
between the third intracellular loop of the D2 receptor and the ATPase 
N-ethylmaleimide-sensitive factor regulating AMPA glutamate receptor-mediated 
excitotoxicity (Zou et al., 2005). Wager-Miller et al (2002) provided biochemical and 
immunocytochemical evidence for CB1 dimerization using a CB1 carboxy 
terminus-specific antibody, which appears to have a high affinity for an oligomeric form of 
the CB1 receptor. They also suggested that the proximal and distal regions of the CB1 
C-terminal might be important contributors to the assembly of the CB1 receptor oligomer 
(Wager-Miller et al, 2002).  
Using in vitro GST and 6His pull-down assays, the present study showed that CB1 
C-terminal (CB1-CT) could pull-down D2 intracellular loop3 (D2-IL3) (Figure 3.41 A), but 
not other D2 intracellular fragments (Figure 3.43), and consistent with this, “D2-IL3” could 
pull-down “CB1-CT” (Figure 3.41 B), but not other CB1 intracellular domains (Figure 
3.42). These results indicate that in vitro direct protein-protein interaction of the CB1 
receptor with the D2 receptor occurs between CB1 intracellular C-terminal (CB1-CT) and 
D2 intracellular loop 3 (D2-IL3).  
To identify the specific fragment in the D2 receptor responsible for the protein-protein 
interaction between “CB1-CT” and “D2-IL3”, the intracellular loop3 of the D2 receptor 
was divided into five fragments (D2-IL3Ⅰ/Ⅱ/Ⅲ/Ⅳ/Ⅴ). In vitro 6His pull-down assays in 
present study indicate that the fourth fragment of “D2-IL3” (D2-IL3 Ⅳ) is the main 
fragment responsible for in vitro coupling between the CB1 and D2 receptors (Figure 3.44). 
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A weaker interaction was noted for the D2-IL3(Ⅲ) fragment. We chose to focus, however, 
on the D2-IL3(Ⅳ) fragment. To further narrow down the specific motifs for further studies, 
the fourth fragment of “D2-IL3” (D2-IL3 Ⅳ) was partitioned into three motifs 
D2-IL3(Ⅳ1/2/3) for in vitro 6His pull-down assays. Results suggest that the first and third 
motifs in the fourth fragment of D2 intracellular loop3 (D2-IL3 Ⅳ1 and Ⅳ3) are likely the 
specific motifs responsible for the in vitro coupling between the CB1 and D2 receptors 
(Figure 3.45). 
    All the evidence obtained so far supports the in vitro direct protein-protein interaction 
between CB1 and D2 receptors, but it still remains unknown whether such protein-protein 
interaction between CB1 and D2 receptors exists in vivo. To answer this question, I have 
performed pilot experiments, in which no specific bands of the D2 receptor could be 
detected when the purified GST tagged fusion proteins of CB1 fragments were employed to 
pull-down D2 receptors from the rat striatum lysate. In the paper reporting the physical 
interaction between CB1 and D2 receptors in transfected HEK293 cells, the amount of 
immunoprecipitated CB1 receptors markedly increased after treating the transfected cells 
with the D2 receptor agonist quinpirole and increasing concentrations of the CB1 receptor 
agonist CP 55,940 (Kearn et al., 2005). Therefore, it is possible that the coupling between 
CB1 and D2 receptors in the striatum may be too minute to be detected in basal in vivo 
condition, although both CB1 and D2 receptor proteins were found to exist in the same 
striatal neurons (Hermann et al., 2002). This working hypothesis is also supported by other 
evidence. An intense signal for CB1 receptor mRNA but low signal for CB1 receptor 
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protein was found in the striatum, whereas no hybridization signal but intense 
immunoreactivity could be detected in the globus pallidus and substantia nigra by in situ 
hybridization and immunohistochemistry methods (Julian et al., 2003). These results 
suggest that CB1 receptors are synthesized in the striatum and most of them transported to 
their target areas, i.e. globus pallidus and substantia nigra (Herkenham et al., 1991a; Julian 
et al., 2003). It is thus plausible to hypothesize that there may not be sufficient amount of 
CB1 receptor protein available in the striatum in basal in vivo situation. Alternatively, there 
might be no physical protein-protein interaction between CB1 and D2 receptors in the rat 
striatum if both CB1 and D2 receptors co-expressed in the same striatal neurons are not 
close enough to allow for a physical interaction or if post-translational modification 
regulates the interaction. Even without the in vivo direct protein-protein interaction 
between CB1 and D2 receptors, convergence in the cellular signaling pathway between 
both receptor systems can occur at the level of G-protein/adenylate cyclase signal 
transduction in the striatum for the mutual regulation of their functions (Ameri, 1999; 
Julian et al., 2003; Meschler and Howlett, 2001; Stelt and Di Marzo, 2003). 
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4.3 Future Direction 
    Further research employing co-IP and semi-in vivo pull-down assay is required to 
determine in vivo protein-protein interaction between the CB1 and D2 receptors in the rat 
striatum. Co-IP is a critical technique for revealing protein-protein interaction in vivo. In 
order to identify protein-protein interaction between the CB1 and D2 receptors in the rat 
striatum, an anti-D2 antibody will be used to immunoprecipitate an immune complex that 
may include physically interacted D2 and CB1 receptors, followed by application of an 
anti-CB1 antibody to detect CB1 receptors from this immune complex by western blot. In a 
parallel experiment, an anti-CB1 antibody will be used first, followed by an anti-D2 
antibody. If positive results are not to be obtained from the co-IP experiments using 
striatum samples in basal in vivo condition, further experiment will be performed to 
investigate whether the protein-protein interaction between CB1 and D2 receptors in the rat 
striatum may occur or be strengthened after activation of CB1 and/or D2 receptors. In 
order to do so, rats will be treated with CB1 receptor agonist, D2 receptor agonist or both, 
followed by dissection of the striatal sample and subsequent performance of co-IP assay. In 
this way, agonist treatment may increase the amount of the CB1 and/or D2 receptor 
proteins so as to facilitate formation of CB1:D2 complexes that could be detected with 
co-IP assay. 
    After verification of protein-protein interaction between CB1 and D2 receptors in the 
rat striatum with co-IP assay, it is important to determine whether the identified specific 
motifs “D2-IL3(Ⅳ1)” and “D2-IL3(Ⅳ3)” in the D2 receptor are indeed critical for D2 
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receptors coupling with CB1 receptors. The ability of the purified peptides of 
“D2-IL3(Ⅳ1)” and “D2-IL3(Ⅳ3)” to disrupt protein-protein interaction between CB1 and 
D2 receptors in co-IP experiments will be examined, in much the same manner as we have 
used relevant peptides to block the interaction between PTEN and the 5-HT2C receptor (Ji 
et al., 2006). If positive results are obtained, the purified peptides of “D2-IL3(Ⅳ1)” and 
“D2-IL3(Ⅳ3)” will be made membrane permeable (Ji et al., 2006) and then utilized to 
assess their suppressing effects on cannabinoid-induced memory impairment and the 
rewarding effects of major drugs of abuse with appropriate behavioral tests. Therefore, a 
better understanding of the protein-protein interaction between CB1 and D2 receptors may 
impact our understanding of the mechanisms that underlie the cannabinoid-induced 
memory impairment and the rewarding effects of major drugs of abuse. Furthermore, the 
specific motifs “D2-IL3(Ⅳ1)” and “D2-IL3(Ⅳ3)” may represent an effective target for use 
as novel therapeutic agents in dopamine-sensitive drug addictions. 
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